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ABSTRACT
Stochastic Modeling and Analysis of Pathway Regulation and Dynamics. (May
2012)
Chen Zhao, B.S., Beijing University of Posts and Telecommunications;
M.Eng., Texas A&M University
Co–Chairs of Advisory Committee: Dr. Edward R. Dougherty
Dr. Ivan Ivanov
To understand effectively and treat complex diseases such as cancer, mathemat-
ical and statistical modeling is essential if one wants to represent and characterize
the interactions among the different regulatory components that govern the underly-
ing decision making process. Like any other complex decision making network, the
regulatory power is not evenly distributed among its individual members, but rather
concentrated in a few high power “commanders”. In biology, such commanders are
usually called masters or canalizing genes. Characterizing and detecting such genes
are thus highly valuable for the treatment of cancer. We present a Bayesian frame-
work to model pathway interactions, and then study the behavior of master genes
and canalizing genes. We also propose a hypothesis testing procedure to detect a
“cut” in pathways, which is useful for discerning drugs’ therapeutic effect.
Another important task in cancer research is to understand the mechanisms of
action (MOA) of cancer drugs. For a new drug, the correct understanding of its
MOA is a key step toward its application to cancer treatments. Using the Green
Fluorescent Protein technology, researchers have been able to track various reporter
genes from the same cell population for an extended period of time. Such dynamic
gene expression data forms the basis for drug similarity comparisons. We design an
iv
algorithm that can identify mechanistic similarities in drug responses, which leads to
the characterization of their respective MOAs.
Finally, in the course of drug MOA study, we observe that cells in a hypothet-
ical homogeneous population do not respond to drug treatments in a uniform and
synchronous way. Instead, each cell makes a large shift in its gene expression level
independently and asynchronously from the others. Hence, to study systematically
such behavior, we propose a mathematical model that describes the gene expression
dynamics for a population of cells after drug treatments. The application of this
model to dose response data provides us new insights of the dosing effects. Further-
more, the model is capable of generating useful hypotheses for future experimental
design.
vTo my wife and my parents
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1CHAPTER I
INTRODUCTION
To effectively understand and treat complex diseases such as cancer, mathematical
and statistical modeling is essential if one wants to represent and characterize the
interactions among the different regulatory components that govern the underlying
decision making process. As we know, cell regulation involves control strategies that
employ multiple inputs, multiple layers of feedback, and nonlinear decision functions.
Owing to the difficulty of modeling and identifying such systems experimentally,
historically biologists have concentrated on marginal interaction between signaling
molecules to construct signaling pathways. Therefore, effectively utilizing the existing
pathway knowledge holds the key for cancer research. In this dissertation, we devote
our efforts to pathway based approach to study gene regulation (Chapter II) and gene
dynamics (Chapter III and IV).
In the context of gene regulation study, we consider three important subproblems:
first, the representation or the modeling of the underlying pathway knowledge; second,
characterizing and detecting master genes and canalizing genes in such model; finally,
drug intervention effects in such network model. Much of our efforts are concentrated
on the second task, since it is believed that master genes or canalizing genes are the
“leverage points” in a network and they could serve as potential therapeutic targets.
In the context of gene dynamics study, we mainly focus on analyzing and com-
paring gene expression dynamic patterns after drug intervention. Such comparisons
form the basis for understanding the mechanism of action (MOA) of cancer drugs,
and therefore are essential for cancer drug development in general. Furthermore, in
The journal model is IEEE Transactions on Biomedical Engineering.
2the course of analyzing gene expression dynamics, we observe that cells in a hypo-
thetical homogeneous population do not respond to the drug treatment in a uniform
and synchronous way. Instead, each cell makes a large shift in its gene expression
level independently and asynchronously from the others. Such phenomenon suggests
that gene expression should be studied on the single cell level to account for the cell-
to-cell variations. A Markov model is proposed to describe gene expression dynamics
for a population of cells after drug treatments. We show that such model is useful
for understanding dosing effects. Finally, we show that the model is capable of gen-
erating useful hypotheses for future experimental design. In the following sections,
we explain each topic in detail.
A. Pathway Regulatory Analysis in the Context of Bayesian Networks Using the
Coefficient of Determination
One of the most important problems in systems biology is to model gene regulatory
networks. Ultimately, the goal is to design proper therapeutic intervention strategies
that can slow down, stop or even reverse the progression of tumors. To this end, there
have been numerous attempts to model gene regulations, ranging from determinis-
tic to stochastic, using either discrete-time or continuous-time descriptions of gene
interactions. Recently, much attention has been devoted to Boolean networks [1] or
probabilistic Boolean networks (PBNs) [2], where gene regulation is formed by a set
of logic operations and the dynamic behavior of networks can be readily studied in
the context of Markov chains. External control policies based on dynamic program-
ming approaches have also been developed to alter the long run behavior of the BN or
PBNs, so that network states are more likely to be in the “desirable” or non-cancerous
states [3, 4]. However, one inherent disadvantage of using BN or PBNs is that the
3number of states grows exponentially with the number of genes in the network, which
makes them difficult to study when the number of constituent genes is beyond 20−30.
Furthermore, the inference of PBNs requires a great deal of temporal data [5], which
is rarely the case in the contemporary microarray based experiments. To alleviate the
complexity problem, researchers have also focused on the state reduction of PBNs [6],
and external control strategies on reduced PBNs [7, 8]. Nevertheless, the complexity
of PBNs still poses a challenge in practice applications. Moreover, optimal control
policy often requires to “flip” a gene according to the corresponding gene activity
profile, which is hard to achieve in practice.
Biology is rich of pathway information that is hand curated and refined by gen-
erations of biologists. In the most basic model, one can view a pathway as originating
with a single regulatory gene (or protein) whose activation initiates a cascade of gene
(protein) responses. Since cell regulation involves a decentralized set of interactions
among various control agents present within the cell upon receipt of external or in-
ternal signals – for instance, activation of a specific gene may require a combination
of transcription factors, and translation to the gene product may be affected by post-
transcription events – if one views the cascade of activities resulting from the action
of a single regulatory gene, both the strength and specificity of subsequent activities
in the cascade may be expected to diffuse through subsequent steps in the cascade.
As the regulatory effects propagate, they are progressively modified or limited by in-
teractions with other factors modulating transcription. From a modeling perspective,
this means that each edge in a pathway has an associated probability and the degree
of regulation exerted by the regulatory gene (protein) at the head of the pathway is
characterized in terms of these probabilities. In fact, except for the activation proba-
bility of the pathway head, each of these probabilities is conditional. Thus, Bayesian
networks can serve as a suitable model for a large portion of genetic pathways and
4the uncertainty classes associated with them. Hence, in Chapter II, we employ a
tree-structured Bayesian network model to represent and characterize the underlying
gene regulations. Note that the purpose is not to propose any new gene regulatory
network model, but is rather to apply a suitable model which can readily incorporate
prior pathway knowledge to study gene regulation. In general, inferring Bayesian net-
work from data is an NP-hard problem [9]. However, in our application, the structure
of the model has already been given from the pathway structures. Thus, only the
parameters of the model need to be estimated from data – a much simpler task to do.
Once the Bayesian networks are constructed from prior pathway knowledge, the
next step is to study and characterize gene regulation in this framework. Like in
any other complex decision making networks, the regulatory power is not evenly
distributed among its individual members, but is rather concentrated in a few high
power “commanders”. In biology, such commanders are usually called master or
canalizing genes. Biologically, the concept of master genes is not new, however, only
until recently, the framework for master genes has been formed mathematically [10],
where it utilizes the Coefficient of Determination (CoD), a measure that quantifies
the predictability of a “target” variable from a set of “predictor” variables, to detect
master genes. In a similar vein, Martins et al. [11] uses a measure called intrinsically
multivariate prediction (IMP) power to characterize and detect canalizing gene, where
a “target” gene is considered to be canalizing if its “predictors” genes do not predict it
well separately, but together, they predict the target gene with high accuracy. While
intuitively appealing, both approaches lack a model-based framework to support their
findings.
The concept of master genes has been explored by other groups as well [12, 13].
In their approach, a reverse engineering algorithm is used to identify master regula-
tors. In their definition, master genes/regulators are genes whose collective behavior
5determines a certain phenotype. To identify such master regulators, an interaction
network consisting of hundreds to thousands of genes is estimated from microarray
gene expression data using the ARACNe algorithm [14]. Hence, it is possible to
associate each transcription factor (TF) with a list A of regulon genes through the
inferred interaction network. In the next step, a list B of signature gene markers
which distinguish between phenotypes are identified by some statistical method (e.g.
t-test or clustering). Next, for each TF, the overlapping score between its regulon
gene list A and the signature gene marker list B is calculated, and master regulators
are defined by the TFs whose overlapping scores are among the highest. Fig. 1 shows
an example of interaction network between the TFs and their targeted mesenchymal
signature genes described in [12]. As can be seen, the network is very complicated
and contains potentially spurious edges. The method is intuitively attractive, how-
ever, there might be several obstacles for such a method to work in practice. First,
the task of inferring an interaction network that consists thousands of genes from
only ∼ 100 of microarray samples is a severely ill-posed inverse problem. Therefore,
the inferred interactions can contain a high false positive rate, even for the proposed
ARACNe algorithm. Second, the tasking of identifying differentially expressed gene
signatures from ∼ 100 microarray samples is again a daunting job. In fact, a range
of recent study [15–17] has shown that error estimation and feature selection is often
intractable in the small sample settings. Thirdly, there is a lack of a coherent, quan-
titative definition for master genes, plus, ranking based on some overlapping scores
can be arbitrary and ad hoc. In fact, recently, in a similar feature ranking problem,
Zhao et al. [18] has shown that the estimated errors for the top features can be overly
optimistic and therefore selection based on top scored features can be misleading.
Nevertheless, the proposed method is still able to find master regulators that are
subsequently verified by biological assays, indicating the fact that master regulators
6Fig. 1. An interaction network showing the regulation between TFs (pink and purple)
and their targeted mesenchymal signature genes (cyan).
exhibit strong control over its slave genes and therefore can serve as potential ther-
apeutic targets. Hence, detecting master genes bears significant biological impacts
towards the treatment of cancer.
In Chapter II, we propose a framework to integrate the two concepts intro-
duced by Dougherty and Martins together. Because in both papers, there is a lack
of network model to represent the underlying gene-gene interactions, it is unclear
what types of nodes will be detected as master genes or canalizing genes and how
the different network parameters will affect their detectability. Toward this end, a
Bayesian network framework is proposed to represent the underlying pathway infor-
7mation with uncertainties. Two measurements called the mean CoD and canalizing
power are introduced to detect master genes and canalizing genes respectively. We
then conduct a series of simulation studies to examine their relationships with various
network structures and parameter values. The results show that both measurements
favor “hub” genes; however, the mean CoD approach measures the ability to control
while the canalizing power approach measures the ability to take over control. Such
subtle difference cannot be appreciated without the help of the proposed network
model. Compared to the work in [12, 13], our network model directly comes from
prior biological pathway knowledge, and the structure of the network is therefore
given, leaving only the parameters of the model to be estimated from data – a much
simpler task than structure inference. In the end of Chapter II, we also utilize the
mean CoD approach to detect a “cut” in the pathways, which provided a formal
statistical approach to discern therapeutic effects.
B. Identifying Mechanistic Similarities in Drug Responses
While it is important to study gene regulations in a probabilistic framework, it is
equally important to study gene expression dynamics, since such time series data
carries rich information about the evolvement of the underlying signaling network. In
the field of cancer drug development, it is often the case that the detailed mechanism
of action (MOA) of a drug is not exactly known, since there might be non-specific
binding of the drug molecule to the host molecules, various cross-talk and feedback
loops to interfere with the drug’s effect, etc. Often, the designed drug fails to meet
the expected therapeutic effects. To understand the MOA of a drug on a particular
cell line, researchers have developed Green Fluorescent Protein (GFP) based method
that allows one to track various reporter genes for an extended period of time (up
8to 50 hours) [19]. The responses are then summarized by the percentage of cells re-
sponded to the drug treatment as well as their averaged fold change. The reporter
genes are selected to represent a wide range of the canonical cellular pathways, such
as the apoptosis pathways, proliferative pathways, and survival pathways, etc. On
the other hand, there are often standard drugs that can attack cell lines at those
canonical pathways. Understandably, these various drugs will induce different re-
sponse characteristics of the cell line, which will then be reflected by the various GFP
reporters. Then, we can narrow down the MOA of the new drug by comparing its
GFP responses to those of the standard drugs, with the premise that two drugs with
similar MOAs should induce similar responses on many of the GFP reporters. As
an example, a panel of GFP reporter responses are shown in Fig. 2. Each column
corresponds to a drug, while each row corresponds to a GFP reporter, with the gene
name shown at the right end of that row. While it is possible to compare reporters
responses in a crude way by looking at the general trend of change [19], a quantitative
approach is desired to compare drug responses in a more objective and automated
way. Hence, there is a need to design proper alignment algorithm to capture the
mechanistic similarities among different drugs.
The study of gene expression time series data is not new. The collection of time
series gene expression has started from the early days of microarrays. One of the
most prominent examples is that of yeast cell-cycle data [20], where the expression
levels of 800 genes in yeast rise and fall as the cells go through their reproductive
cycle. Khodursky et al [21] measured gene-expression time series in E. coli in order
to characterize the genes regulating the bacteria’s synthesis of the amino acid trypto-
phan, in part by observing gene activities over time when the bacteria were exposed
to different amounts of external stimuli.
Traditionally, the comparisons of gene expression time series data have been
9Fig. 2. Gene response dynamics induced by four different drugs on cell line HCT116.
The upper panel of each barplot shows the population change and the lower
panel shows the corresponding fold change. Red color indicates down-regula-
tion and green color indicates up-regulation.
mostly focused on the so called dynamic time warping (DTW) methods, originally
developed by Sakoe and Chiba [22] in the speech recognition community. Aach and
Church [23] were the first to apply the method to microarray gene expression profiles,
and other groups have followed suit [24, 25]. Briefly, the DTW algorithm works by
locally deforming the time axis in order to minimize the cumulative difference between
the aligned points. The rationale behind this approach is that biological processes
are time elastic, meaning that multiple instances of a single process may unfold at
different and possibly non-uniform rates. Therefore, to maximize the similarity, one
needs to align them appropriately. Fig. 3 illustrates the type of alignment commonly
used in the DTW method.
For several reasons, direct application of DTW type of algorithms is not appli-
cable to the comparison of drug MOAs. First, the goal of DTW is to minimize some
cumulative score (usually normalized Euclidean distance), which has no direct biolog-
10
Fig. 3. Schematic figure to show dynamic time warping alignment of two time series
data. Time axis is deformed to minimize the cumulative Euclidean distance
between the two.
ical meaning. Second, DTW is sensitive to outliers, which can distort the alignment
results significantly if present in the signal. Finally, DTW treats all the data points as
equally important, however, in the drug response data, the “core” information about
the MOA of drugs lies in the region where sufficient cells have responded to the drug.
Hence, a good alignment algorithm should bias toward that region to maximize the
meaningful biological similarity.
In Chapter III, we propose a recursive method that utilizes the concept of longest
common substring idea to iteratively identify biologically interesting similarities in
drug response data. The proposed algorithm is able to overcome all of the aforemen-
tioned weaknesses of the DTW type algorithm. Applying our algorithm to a range of
real drug experiments shows that the newly proposed algorithm is accurate, sensitive
and consistent with existing drug MOA knowledge.
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C. Modeling Population of Cells’ Gene Expression Dynamics after Drug Treatment
Researchers have long realized that gene expression can exhibit a significant degree of
variations from cell to cell, even in a hypothetical homogeneous cell population. Many
models are proposed to describe such phenomenon. In one possible explanation, the
randomness is attributed to the inherent stochasticity in the biochemical process of
gene expression (intrinsic noise) or fluctuations in other cellular components (extrinsic
noise) [26]. Another theory indicates that gene expression is governed by “transcrip-
tion bursts”, where a gene stays a long time in the inactive state, followed by a short
period of active state where it makes a burst of transcripts [27]. Such random bursts
lead to different amounts of transcripts inside different cells.
Interestingly, in the course of analyzing gene expression dynamics, we also ob-
serve stochasticity among different cells after drug treatments. Briefly, each cell makes
a large shift in its gene expression level independently and asynchronously from the
others. And the onset response times can vary drastically from cell to cell: some cells
respond to the drug very early, but some could respond to the same drug 40 hours
later. Intuitively, one can view the drug’s effect in any single cell as ineffective or
effective. When it is ineffective, a cell stays in its original expression state with a
high probability; however, when the drug is effective, it becomes possible for a cell
to switch its expression state probabilistically. Therefore, a hybrid system describing
the onset response times (modeled as a family of logistic functions) of individual cells
as well as the gene expression state transition (modeled as hidden Markov model
(HMM)) in each cell is proposed in Chapter IV to describe gene expression dynamics
after drug treatment. The model contains key parameters that are biologically rele-
vant, furthermore, we show the model is useful for understanding dosing effect and is
capable of generating useful hypotheses for future experimental design.
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The use of hidden Markov model has numerous applications, including speech
recognition [28], bio-sequence alignment [29, 30], image processing [31, 32], etc. In
the field of GFP based cell tracking, Wang et al [33] has recently proposed a HMM
based approach to infer cell cycle states from features such as cell shape, size and
intensities, etc. However, like in most of the HMM based approaches, their focus is to
infer the “correct” hidden states given the observed data. Such problem does not exist
in our applications – the hidden gene expression states are directly observable due
to the existence of control experiments (see Chapter IV for a detailed description).
Therefore, for the model parameter estimation part, we focus on the inference of onset
response times, which is critical for understanding dosing effects.
It should be emphasized that our model assumes the gene regulation is governed
by two regulation states or regulation contexts – drug ineffective or drug effective. In
the two contexts, the associated Markov model has different transition probabilities.
A similar contextual regulation idea was previously introduced in [10]. In that paper,
the authors assumed that the context is determined by latent variables which lead
to probabilistic gene regulations. Compared to their approach, we explicitly model
the contexts as drug effects, and more importantly, we consider the gene expression
dynamics rather than static gene regulations.
D. Dissertation Outline
The remainder of this dissertation is organized as follows:
• In Chapter II, we first introduce the tree based Bayesian network to model
pathway regulations. Two important parameters – cross-talk and conditioning
are used to quantify the tightness of regulation between a parent node and its
child node. Following the modeling part, we introduce two measurements that
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are used to detect master genes and canalizing genes, respectively. We then
study the effects of network structure and parameters on the detectability of
master genes and canalizing genes. In the end of Chapter II, we formulate a
hypothesis testing procedure to detect a “cut” in pathways.
• In Chapter III, we first formulate the gene expression dynamics alignment prob-
lem conceptually, and state explicitly what types of mechanistic similarities are
important for the understanding of drug MOAs. Then, we introduce a recursive
time series alignment algorithm to iteratively identify such similarities in drug
response data. Finally, we apply the proposed method to a set of real drug
experiments to evaluate its performance.
• In Chapter IV, we introduce a Markov model to describe gene expression dy-
namics for a population of cells after drug treatment. Then, we discuss how to
infer model parameters from both synthetic and real data. The results show
that the model is useful for understanding dosing effects.
• In Chapter V, we summarize the main contributions of the work and discuss
some future directions of research.
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CHAPTER II
PATHWAY REGULATORY ANALYSIS IN THE CONTEXT OF BAYESIAN
NETWORKS USING THE COEFFICIENT OF DETERMINATION∗
This chapter presents a model based approach to study master genes and canalizing
genes. To set the stage, we first introduce the concept of master genes in the context of
pathway regulations and give the rationale of using tree structured Bayesian network
to model gene regulations. Then, we propose two measurements to quantify master
genes and canalizing genes in the network model respectively. Their behaviors are
studied systematically by varying the network structures and parameters. In the end,
we also propose a hypothesis testing procedure to test a “cut” in the network model,
which is potentially useful for discerning drug therapeutic effects.
A. Pathway Knowledge and Bayesian Network
Differentiated cells in a mature organism spend most of their time maintaining a set
of activities that either support their own persistence or contribute to the persistence
of the organism of which they are a part. In this state, regulation in the cell is
mostly fine-tuning and integration of these established activities and does not involve
massive shifting of regulatory states. However, when the cell must coordinate the
various intermittently used processes required to achieve other particular operations,
such as repairing extensive DNA damage that arose as a result of some environmental
insult or entering the cell cycle to produce a daughter cell, large changes in regulation
are required. As in any system, excursion away from the normal state of processing
∗ c©2011 Journal of Biological Systems Reprinted, with permission, from ”Path-
way regulatory analysis in the context of Bayesian network using the coefficient of
determination” by C. Zhao, I. Ivanov, M. L. Bittner, E. R. Dougherty, 2011, Journal
of Biological Systems, 19(4):651-682.
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may drive the system to a point from which it cannot return to its normal state. In
biology one of the largest dangers associated with either loss of the ability to perform a
complex corrective action or the loss of the ability to cease operating in a proliferative
mode that produces an excess of cells is cancer. To effectively intervene when cells are
trapped in pathological modes of operation it is necessary to build models that capture
relevant network structure and include characterization of dynamical changes within
the system. The model must be of sufficient detail that it facilitates the selection of
intervention points where pathological cell behavior arising from improper regulation
can be stopped.
Cell regulation involves control strategies that employ multiple inputs, multi-
ple layers of feedback, and nonlinear decision functions. Owing to the difficulty of
modeling and identifying such systems experimentally, historically biologists have
concentrated on marginal interaction between signaling molecules to construct sig-
naling pathways. In the most basic model, one can view a pathway as originating
with a single regulatory gene (or protein) whose activation initiates a cascade of gene
(protein) responses. Since cell regulation involves a decentralized set of interactions
among various control agents present within the cell upon receipt of external or in-
ternal signals – for instance, activation of a specific gene may require a combination
of transcription factors, and translation to the gene product may be affected by post-
transcription events – if one views the cascade of activities resulting from the action
of a single regulatory gene, both the strength and specificity of subsequent activities
in the cascade may be expected to diffuse through subsequent steps in the cascade.
As the regulatory effects propagate, they are progressively modified or limited by in-
teractions with other factors modulating transcription. From a modeling perspective,
this means that each edge in a pathway has an associated probability and the degree
of regulation exerted by the regulatory gene (protein) at the head of the pathway is
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characterized in terms of these probabilities. In fact, except for the activation proba-
bility of the pathway head, each of these probabilities is conditional. Thus, Bayesian
networks can serve is a suitable model for a large portion of genetic pathways and the
uncertainty classes associated with them. This chapter provides a modeling frame-
work for pathway representation in the context of Bayesian networks and examines
several issues.
To illustrate the pathway scenario, consider the Ras pathway model in Fig. 4.
Mutant Ras proteins are found in 20-25% of all human tumors and up to 90% in
specific tumor types [34]. The Ras protein sits in the middle of a complex signaling
cascade and it functions as a binary switch that controls intracellular signaling net-
works. Once the extracellular signals are received by the receptor proteins located
in the cell membrane and passed on to Ras, it then will transmit the signal to three
major downstream pathways involved in cell proliferation, differentiation, apoptosis,
etc [35]. In a nut shell, the upstream proteins of Ras are summarized by Receptor →
Shc → Grb2 → Sos → Ras, and the three major downstream pathways of Ras are
illustrated by Fig. 4. The Ras pathways form a tree structure, where many branches
are downstream from Ras. This structure helps to explain why Ras is powerful as a
potent oncoprotein and is able to drive the cell to neoplastic transformations. On the
other hand, one would expect that the deregulation of downstream proteins of Ras
may possess far less transforming power as compared to Ras. Indeed, the point is
illustrated nicely by the mutant B-Raf kinase, the close cousin of Raf, which is also
activated by interaction with Ras. These mutations, which are found in many human
melanomas, create oncogenic BRAF alleles that have transforming powers that are
only about one-fiftieth of those for the activated Ras oncoprotein [36]. Presumably,
signaling components located further downstream, when altered by mutation, con-
fer even less transforming power [35]. The model proposed in this chapter provides
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Fig. 4. The Ras protein network.
a mathematical way to characterize these kinds of behaviors, specifically, to model
protein-protein (gene-gene) interactions in the framework of graphical models and
study their regulatory importance within the model.
This kind of pathway information can play an important role in developing com-
putational methods for identifying and validating drug targets. For instance, in Imoto
et al. [37], the authors discuss how Bayesian networks can be inferred from microarray
data and then used to identify their respective root nodes as the potential regulators
or, as the authors term them, “druggable genes”. There are several major differences
between our work and what is discussed in that chapter: first, our analysis does not
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begin with network inference, rather, the pathway structure is given as prior knowl-
edge and the conditional probabilities, i.e., model parameters, are inferred from data
by standard statistical techniques; second, we focus on characterizing important nodes
(canalizing and master genes) in the model; third, we also discuss statistical testing
procedures for detecting pathway disruption. Pathway disruption has previously been
considered from a purely logical perspective by treating a set of pathways as a de-
terministic wiring diagram and then applying classical fault-detection to determine
suitable drug combinations [38], but that analysis did not involve any probabilistic
considerations. More generally, one could consider various cell-line platforms for the
purposes of drug discovery and validation [39]. Such platforms can potentially benefit
from our proposed framework that allows for statistical testing of drug disruption of
known cell regulatory pathways.
Looking at Fig. 4 from a local perspective, except for the genes at the bottom of
the cascade, each gene may be considered as a master for the gene below it, which can
be considered as its slave. Moving up a level of perspective, PI3K, Raf, and Ral-GEF
may be considered masters for their respective branches, with each gene in a branch
being a slave for its respective master. Taking a maximally global perspective, if
we consider the sequence Shc → Grb2 → Sos → Ras as a communication channel
from the Receptor to Ras, then Ras can be considered as a system master with all
other genes in the full downstream pathway being considered its slaves [36]. (From a
logical perspective, one could alternatively consider Shc as a system master, in which
case Ras would lie within the Shc system.) If gene g is a master for a collection of
slave genes, then we would expect that activation of g would be predictable from
observation of the slaves and that the wider the swath of control exercised by g, the
greater the extent of that predictability as we consider more genes in the network. It
is important to emphasize that the concept of a “master” is both relative and local.
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A gene that is a “master” for a given portion of a regulatory network could be a
“slave” in a different context, e.g., network segment.
The problem considered in Dougherty et al. [10] was to quantitatively character-
ize master genes, more specifically, the power of master genes, via the ability to predict
their behavior from the behavior of other genes. Predictive strength was quantified
via the Coefficient of Determination (CoD), which quantities the increased ability to
predict a random variable via a set of “predictor” random variables as opposed to
merely predicting it from its own statistics. The model constructed in that paper
was purely probabilistic, without any structural considerations. Here we consider the
master-slave paradigm in the framework of a Bayesian pathway model. This approach
allows a finer characterization of master-slave behavior and allows us to quantitatively
characterize regulatory strength in terms of the branching structure of control.
Related to master genes are genes that can constrain, or canalize, a biological
system to particular options [40]. We are not referring to sequential canalization,
whereby a specific action of the master enforces a cascade of actions among a single
highly correlated cohort of genes important in a single process, but rather where a
gene has such broad regulatory power, and its action sweeps across such a wide swath
of processes, that the full set of affected genes are not highly correlated under normal
conditions. Early observations of canalization along the mitogenic pathway involved
the Ras gene family, members of which were found to have frequent mutations in
their twelfth codon in cancers that produce uncontrolled proliferation [41]. Another
significant instance of canalization involves the gene TP53 in regard to stresses to
the genome [42]. A key characteristic of a canalizing gene is its ability to override
other regulatory instructions if the condition of the cell so warrants. This affects the
predictability of the controlling (canalizing) gene by those genes it controls. This
property has led to the characterization of canalization via intrinsically multivariate
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prediction (to subsequently be defined rigorously), which relates to the ability of a
full set of predictors to provide excellent prediction, whereas leaving out any one of
the predictors greatly reduces prediction accuracy [11]. In analogy to the master-
slave paradigm in Dougherty et al. [10], canalization is characterized in Martins et
al. [11] by the CoD absent a structural model. Here we will characterize canalization
in the context of pathways, thereby taking into account structural considerations, and
provide a clear discrimination between a master gene and a canalizing gene. Thus,
our approach provides a framework, rather than an algorithm, for modeling specific
regulatory structures or pathways and their respective uncertainty classes commonly
observed in the context of cell regulation. The framework is outlined on Fig. 5, which
also emphasizes the relationships among different sections in the chapter.
B. Background
1. Bayesian Networks
Given a random vector X = (X1, X2, . . . , XN), a Bayesian network B = (G,Θ) is
defined by: (1) a directed acyclic graph (DAG) G whose vertices correspond to X1,
X2, . . ., XN and (2) a set Θ of local conditional probability distributions for each
vertex Xi, given its parents in the graph [43–45]. The graph encodes the “Markov
assumption,” which states that each variableXi is independent of its non-descendants,
given its parents in G. By the chain rule of probabilities, any joint distribution
satisfying the Markov assumption can be decomposed into a product of the local
conditional probabilities. Letting Pa(Xi) denote the Markovian parents of Xi in the
graph G, the joint probability distribution (JPD) P is completely specified by
P (X1, X2, . . . , XN) =
N∏
i=1
P (Xi|Pa(Xi)) (2.1)
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pathway.
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Fig. 6. A tree with the root node X1.
where P (Xi|Pa(Xi)) specifies the conditional probability table (CPT) for Xi and
we refer to the parameters that determine P (Xi|Pa(Xi)), i = 1, 2, . . . , N , as the
parameters of the Bayesian network. Here, we consider the binary case, Xi = 0 or
1; however, the results can be easily extended to discrete-valued random variables
which assume any pre-specified set of values.
We focus on Bayesian networks, whose DAGs are trees: the DAG has a unique
root node with no parents and every other node has precisely one parent and is a
descendent of the root [45,46]. A tree is shown in Fig. 6, the root being X1.
Once the DAG of a Bayesian network and its associated CPTs are given, the
joint distribution is determined by Eq. (2.1) and the joint distribution of any subset
of the nodes can be computed from the full joint distribution by summing out the
nodes not in the subset. However, this approach is inefficient, since the number of
operations grows exponentially with the number of nodes outside the subset. Many
efficient inference methods exist for Bayesian networks. It should be noted that Pearl
developed a message-passing algorithm for exact inference in Bayesian networks with
tree structures. The algorithm proceeds by passing two types of messages among
neighboring nodes iteratively and computing the conditional probabilities of interest
by updating the two types of messages [47]. Using the message passing algorithm, we
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Table I. CPT of Xi in the tree model.
P (Xi = 0|Xj = 0) = 1− ηji P (Xi = 1|Xj = 0) = ηji
P (Xi = 0|Xj = 1) = δji P (Xi = 1|Xj = 1) = 1− δji
can compute the joint distribution of any subset of variables in the tree efficiently.
The parameters of a tree are specified as follows. Let Xr be the root of the tree.
Let Cr,0 = P (Xr = 0) and Cr,1 = P (Xr = 1). If Xj is the parent of Xi, then the
CPT of Xi is given by Table I, where δji is the “conditioning parameter” between
Xj and Xi and its magnitude depends on the extent to which the influence of Xj on
Xi is diminished by contextual effects and ηji is the “cross-talk parameter” and its
magnitude depends on the effects of other nodes during the periods when the parent
Xj is not actively regulating Xi [10]. Intuitively, if both δji and ηji are small, then
the regulation between Xj and Xi should be tight; conversely, if both δji and ηji are
large, then the regulation should be loose. The marginal distribution of any node is
easily computed once the parameters of the tree are given. We let Ci,0 = P (Xi = 0)
and Ci,1 = P (Xi = 1).
Our interest is to model signaling pathways with uncertainties in gene regulation.
Although every node, except the root, in the tree has only one parent, this does not
mean that each gene has only one physical regulator in the actual pathway. In fact,
Xi could have multiple regulators, Xj, Xj+1 , . . . , Xj+q, and this regulation could
change in different cell contexts. By focusing on the relation between Xj and Xi,
the regulation appears random rather than deterministic and we use the cross-talk
and conditioning parameters to capture the uncertainties. In this sense, the tree
model is a higher level abstraction of gene regulation rather than a model of the
detailed physical interactions among different genes. It is important to recognize that
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Fig. 7. Two basic types of trees.
the overall effect of cross-talk and conditioning depend on where they occur in the
pathway. Furthermore, the structure of the model (that is, nodes and edges) is not
restricted only to gene-gene interactions. It can also be used to model more general
relationships between various factors participating in cell regulatory pathways, for
example, signaling molecules and/or proteins represented by network nodes and their
probabilistic relationships represented by network edges.
A salient attribute of Bayesian networks is their ability to encode conditional
independencies among variables, which reduces significantly the number of parameters
required to represent a complex joint distribution and facilitates efficient probabilistic
computations. In fact, given the DAG of a Bayesian network, we can directly read
properties of conditional independencies between random variables. For example, for
the tree in Fig. 7(a), given X2, X1 is independent of Xi, for i = 3, . . . , n; indeed,
P (X1|X2) = P (X1|X2, X3, . . . , Xn). Intuitively, the information flow from X1 to Xi
is blocked once X2 is known. For Fig. 7(b), given X1, X2 is independent Xi, for
i = 3, . . . , n; indeed, P (X2|X1) = P (X2|X1, X3, . . . , Xn) [46].
2. Coefficient of Determination
The Coefficient of Determination(CoD) measures the relative decrease in error when
optimally predicting a random variable X using random vector Y as opposed to
optimally predicting X based only on its own statistics. Formally, the CoD for Y
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predicting X is defined in Dougherty et al. [48] by
CoDY(X) =
ε0(X)− ε•(X,Y)
ε0(X)
(2.2)
where Y is a random vector composed of r “predictor” random variables, which are
used to predict the status of the “target” node X, ε0(X) is the mean-square error
(MSE) for predicting X using only its own distribution, and ε•(X,Y) is the minimal
MSE for using Y to predict X, which means that it is the minimal error achieved over
all possible functions that predict the value of X from the values of the components
of Y [48]. When using the CoD we are not interested in any particular function
of Y that predicts X; rather, we are only concerned with the performance of the
optimal prediction of X based on Y. It is in this way that the CoD determines the
inherent strength of the connection between a target gene and its predictors. The
CoD measures nonlinear interaction and is therefore more appropriate to genomics
than the correlation coefficient, which only measures linear interaction.
The CoD has been used since the early days of microarray analysis to characterize
the nonlinear multivariate interaction between genes, where the problem was to utilize
expression measurements to determine whether or not the expression level of one
gene can be predicted by the values of others, with gene expression quantized to
three levels: 1 (up-regulated), −1 (down-regulated), and 0 (invariant) [49]. The CoD
measures nonlinear association (increase in prediction power), not causality. When
CoDY(X) is high, it does not indicate that the set Y of genes regulates X (directly or
indirectly); instead, it could mean that X regulates the random variables composing
Y (directly or indirectly). Indeed, herein, the CoD will be used to measure the
strength of downstream genes predicting upstream genes. The intuition is that, if
gene g regulates genes g1 and g2, the observation of g1 and g2 should allow one to
predict the behavior of g, the stronger the control by g, the stronger the prediction.
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Owing to its ability to quantify the degree of interaction, the CoD has been used
for numerous purposes in genomics, including: iteratively growing gene regulatory
networks from seed genes by adjoining new genes strongly connected to those cur-
rently included in the growing network [50], characterization of canalizing genes [11],
the identification of master genes [10, 51], and the reduction of gene regulatory net-
works for the purpose of lowering computational complexity while at the same time
preserving regulatory information [7]. Since, in practice, the CoD is typically esti-
mated from data, error estimation performance is a key issue and performance com-
parison among commonplace estimation procedures (resubstitution, cross-validation,
and bootstrap) has been studied [52].
We restrict ourselves to the binary case (0 and 1); however, the basic definition
for CoDY(X) is not so restricted. In the binary setting, there are simple expressions
for ε•(X,Y) and ε0(X) ; Letting y1, y2 ,. . ., y2r , denote the 2r possible values for Y,
running from (0, 0, . . . , 0) to (1, 1, . . . , 1),
ε0(X) = min{(X = 0), p(X = 1)}
ε•(X,Y) =
2r∑
j=1
min{P (X = 0,Y = yj), P (X = 1,Y = yj)}
(2.3)
where the computation of ε•(X,Y) requires the joint distribution of X and Y.
Note that conditional independencies are important in calculating CoDs. For ex-
ample, in Fig. 7(a), CoDX2,X3(X1) = CoDX2(X1) because P (X1|X2, X3) = P (X1|X2).
Intuitively, X3 is blocked by X2 and does not provide any additional information in
predicting X1.
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C. CoD and Basic Tree Structures
To understand the relationships between the CoD, the cross-talk and conditioning
parameters, and the tree structure, we start by investigating two basic structures in a
tree. The three-node chain in Fig. 8(a) possesses the JPD in Table II. The marginal
probability distribution for X1 and X3 is given in Table III.
X3
X1 X2
X1 X2 X3
(a) (b)
Fig. 8. Two three-gene trees.
Table II. Joint probability distributions of a 3-gene chain shown in Fig. 8(a).
X1 X2 X3 JPD
0 0 0 C1,0(1− η12)(1− η23)
0 0 1 C1,0(1− η12)η23
0 1 0 C1,0η12δ23
0 1 1 C1,0η12(1− δ23)
1 0 0 C1,1δ12(1− η23)
1 0 1 C1,1δ12η23
1 1 0 C1,1(1− δ12)δ23
1 1 1 C1,1(1− δ12)(1− δ23)
Consider the special case when η12 = δ12 = η23 = δ23 = a. Then η13 − η12 =
δ13 − δ12 = a− 2a2 > 0 for 0 < a < 0.5. The regulation becomes weaker as the signal
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Table III. Marginal probability distributions for the 3-gene chain shown in Fig. 8(a) :
η13 = (1− η12)η23 + η12(1− δ23) and 1− δ13 = δ12η23 + (1− δ12)(1− δ23).
X1 X3 JPD
0 0 C1,0(1− η13)
0 1 C1,0η13
1 0 C1,1δ13
1 1 C1,1(1− δ13)
propagates along the pathway, the diminishing regulation depending on a, as shown
in Fig. 9. Note that CoDX3(X1) < CoDX2(X1), since X1 loses its control along the
path with increased cross-talk and conditioning. As in Fig. 8(a), CoDX2,X3(X1) =
CoDX2(X1). This relationship does not result from the specific choice of the cross-talk
and conditioning parameters; it is solely determined by the independencies encoded
in the 3-gene chain.
The JPD for the 3-gene branch in Fig. 8(b) is given in Table IV. If we assume the
same parameter settings as in the 3-gene chain, then CoDX2(X1) = CoDX3(X1) =
CoDX2,X3(X1), as shown by the dashed line in Fig. 9. Considering a more interesting
example in Fig. 10, we let δ12 = δ13 = b, with 0 ≤ b ≤ 0.5, we fix η12 = η13 = a = 0.5,
and let C1,0 = 0.5. The intention of this choice is to see the behaviors of CoD values
of X1 when the cross-talk is high and the conditioning varies from low to high. We
see that CoDX2,X3(X1) > CoDX2(X1) in Fig. 10. Intuitively, because X2 and X3 are
in different branches originating from X1, they provide complementary information
about X1, thereby resulting in an increase in prediction power.
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Fig. 9. CoDs for a 3-gene chain shown in Fig. 8(a): C1,0 = 0.5 and
η12 = δ12 = η23 = δ23 = a. Note that CoDX3(X1) < CoDX2(X1), because
X1 loses its control power over X3 along the path with increased cross-talk and
conditionings.
D. Master/Slave Paradigm
1. Master and Slave Genes in the Context of a Bayesian Network
The master-slave paradigm explores the relationship between the CoD histograms
of a particular gene and its regulatory importance [10]. The CoD histogram for a
particular gene is generated by computing CoD values by all possible predictor sets
of size r. For example, if there are a total of 10 genes of interest and if we consider
all possible pairs of predictors, the CoD histogram of any given gene should include
C(9, 2) = 36 CoD values. It was hypothesized that CoD histograms skewed to the
right (high mean CoDs) correspond to master genes and CoD histogram skewed to
the left (low mean CoDs) correspond to slave genes [10]. This interpretation is based
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Table IV. Joint probability distributions of a 3-gene branch shown in Fig. 8(b).
X1 X2 X3 JPD
0 0 0 C1,0(1− η12)(1− η13)
0 0 1 C1,0(1− η12)η13
0 1 0 C1,0η12(1− η13)
0 1 1 C1,0η12η13
1 0 0 C1,1δ12δ13
1 0 1 C1,1δ12(1− δ13)
1 1 0 C1,1(1− δ12)δ13
1 1 1 C1,1(1− δ12)(1− δ13)
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Fig. 10. CoDs for a branch shown in Fig. 8(b): δ12 = δ13 = b, with with 0 ≤ b ≤ 0.5,
η12 = η13 = a = 0.5, and C1,0 = 0.5. Note that CoDX2,X3(X1) > CoDX2(X1),
because X2 and X3 can provide complementary information about X1.
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on the observation that if a master gene potentially regulates many other slave genes,
then many of the pairs formed by those slave genes should serve as good predictors
for the master, thereby producing high CoDs. In this chapter, rather than relying on
a general interpretation of the CoD, we examine the matter in the framework of a
tree model representing regulatory pathways. In particular, we relate the mean CoD
values of a gene to its regulatory importance in the model.
It should be noted that the concept of master/slave model was originally proposed
using the Boolean formalism, where the output of the Boolean functions may vary
depending on particular contexts or hidden variables [10]. The notions of cross-talk
and conditioning were introduced to incorporate these uncertainties. In the current
Bayesian-network framework the source of uncertainty may include this interpretation
but is not limited to it.
The mean CoD of a node Xi using all single predictors in a tree dis given by
CoDS(Xi) =
N∑
j=1,j 6=i
CoDXj(Xi)
N − 1 (2.4)
The mean CoD of a node Xi using all double predictors in a tree is given by
CoDD(Xi) =
∑
16j<k6N,j,k 6=i
CoDXj ,Xk(Xi)
C(N − 1, 2) (2.5)
Eq. (2.5) gives the average strength of predicting Xi by using all of the possible pairs
of the rest of the genes in the network. Intuitively, if Xi is a master gene, then, its
activity should be able to influence many of its slave sets and therefore, CoDD(Xi)
should be high [10].
Consider the tree in Fig. 11, where for illustration purposes we assume common
cross-talk and conditioning parameters for each node. We plot the mean CoD of
each node as a function of the two parameters and visualize the changes directly.
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X1 X2 X3
X4 X5
Fig. 11. A tree with 5 layers and 15 nodes. Due to symmetry, only one representative
gene on each layer is annotated, assuming common cross-talk and conditioning
parameters for each node.
Furthermore, we can compare the mean CoD plots for different genes and see how
they reflect their respective regulatory importance.
CoDD(Xi) for each Xi and two-gene prediction is plotted in Figs. 12 and 13
as a function of η and δ, assuming C1,0 = 0.5 and C1,0 = 0.1 in Figs. 12 and 13,
respectively – The brighter the image, the higher the mean CoD values. We observe:
(1) The node X3 has the highest mean CoDs, indicating that the “hub” gene is likely
to be detected as the master gene using CoDs; (2) the node X5 has relatively low
mean CoDs, indicating that the downstream gene is likely to be detected as a slave
gene by the CoD approach; and (3) when C1,0 = 0.1, CoDD(X1) is extremely low,
which occurs because ε0(X1) = 0.1 and therefore it is hard to achieve an increase of
prediction by other genes. Were there no cross-talk or conditioning between the root
and the hub, then they would be equivalent relative to CoDD(Xi) and therefore the
root would also be detected.
Having observed that the mean CoD approach tends to detect hub genes in the
tree model, we now investigate how the mean CoD changes with respect to the number
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Fig. 12. Plots of CoDD(Xi) corresponding to the tree in Fig. 11, with C1,0 = 0.5.
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Fig. 13. Plots of CoDD(Xi) corresponding to the tree in Fig. 11, with C1,0 = 0.1.
X1 X2 X3
X4 X5
Fig. 14. A tree with 5 layers and 7 nodes.
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Fig. 15. Plots of CoDD(Xi) corresponding to the tree in Fig. 14, with C1,0 = 0.5.
Table V. Comparisons for overall double mean CoD intensities for X1 through X5 in
two different trees. The values for the 15-node tree and 7-node tree represent
the overall intensities of each gray scale image in Figs. 12 and 15, respectively.
CoDD(X1) CoDD(X2) CoDD(X3) CoDD(X4) CoDD(X5)
15-node tree 641.49 736.76 1006.1 597.73 350.52
7-node tree 826.78 903.78 994.1 771.86 496.94
of branches in the model. Consider the tree in Fig. 14, which is similar to the tree in
Fig. 11 except that the hub gene X3 has only 2 branches going out. CoDD(Xi) for
each Xi is plotted in Fig. 15 as a function of η and δ, assuming C1,0 = 0.5. Since less
outgoing branches suggests less genes controlled by that gene, we expect CoDD(X3)
to be lower in Fig. 14 in comparison to Fig. 11. Table V confirms this expectation.
In particular, the hub gene X3 stands out more from the rest of the genes in the
15-node tree because it controls more branches.
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2. An Example of a TP53 Pathway
In this section we construct a TP53 pathway to illustrate the pathway methodology
being developed. The NCI 60 ACDS is a set of widely studied human cancer cell lines
derived from cancers of colon, breast, ovary, lung, kidney, prostate, central nervous
system, skin, and bone marrow. In the original study, duplicate cultures of 64 cell
lines were either irradiated with a high dose of ionizing radiation and harvested four
hours later or left untreated and harvested four hours later. From the entire data
set, 40 cell lines containing an equal number of TP53 positive and TP53 negative
members were chosen to allow investigation of radiation response in cells. The data
are binarized and, from an original set of 496 genes, a subset, A, of 96 genes is
kept eliminating those with variance not exceeding 0.19 (see [10] for more details on
the data set). We obtain a cell cycle, cancer and cell death network generated by
Ingenuitiy (http://www.ingenuity.com/). This network is curated purely based on
expert knowledge and contains a total of 35 genes (not shown). 16 of these 35 belong
to A. If we focus on the connections between TP53 and the other 15 genes, we obtain
a simplified tree structure whose root is TP53 (Fig. 16). Although the proposed
simplification could lead to loss of information embedded in the original network, it
aims to capture the regulatory power of TP53.
To illustrate how the tree model and the proposed mean CoD approach can be
used for the purposes of master gene characterization, we performed the following
experiment.
1. Given the tree structure Bayesian network on Fig. 16, we estimated the associ-
ated network parameters from the 40 samples. Specifically, for each node in the
tree, the conditional probabilities of it being ON or OFF given its parent was
estimated using the Bayesian estimation approach with Beta(1, 1) prior [46].
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Fig. 16. A tree model for TP53.
2. For each node in the tree, we drew values for the cross-talk and conditioning
parameters from their respective posterior Beta distributions, see step 1. Once
the parameters were drawn for all of the nodes in the tree, we calculated the
single-gene mean CoD for each node in the tree, as shown in Eq. (2.4).
3. We repeated the previous step 1000 times, so that for each node, 1000 single-
gene mean CoDs were calculated. The histograms for the 6 representative genes
from Fig. 16 are shown on Fig. 17.
4. We also calculated the empirical single-gene CoD for each gene directly from
the 40 samples (red crosses shown on Fig. 17). The empirical CoD calculations
were done similar to what is described in Section C of this chapter, except that
the joint probability distributions were replaced by the maximum likelihood
estimations calculated from the 40 samples. Interested readers should refer
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Fig. 17. Single-gene mean CoD distributions for 6 representative genes in Fig. 16.
The red-cross indicates the empirical-mean CoD computed directly from the
40 samples. Note that the mean CoD of TP53 stands out from the rest of the
genes, indicating its role as a master regulator.
to [52] for a detailed study of various CoD estimators.
This example shows that the model can capture the regulatory power of TP53
and the behavior of the other 15 genes in the sense that all of the empirical-mean
CoDs are within the 0.95 confidence interval of the mean CoDs obtained from the tree
model, i.e., the red crosses in Fig. 17 agree well with the means of their respective
histograms. Moreover, TP53 shows up as the master gene, in the sense that it has
the biggest single-gene mean CoD.
E. Canalizing Genes
The first quantitative study of canalization was in the context of logical functions in
the Boolean network framework [1, 53–55]. A canalizing function is one in which at
least one of the input variables has one value that is able to determine the value of the
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output of the Boolean function, regardless of the other variables [55]. For example,
the Boolean function Z = X ∨ Y is a canalizing function, since X = 1 implies Z = 1,
regardless of the value of the input variable Y . There is also evidence that many
control rules governing transcription of eukaryotic genes are canalizing when viewed
in the Boolean formalism [56]. The preceding definition of a canalizing function
attempts to characterize canalizing genes locally from the perspective of Boolean
logic; however, it does not characterize the role of canalizing genes from a network
perspective, i.e. globally. In this section, we define and study the canalizing properties
of a gene in the proposed tree model. As explained later, such definition favors genes
that are directly connected to multiple branches in the model, and therefore have the
potential to take over the control of many pathways.
1. Canalizing Gene Definition in the Tree Model
Previously, Intrinsically Multivariate Predictive (IMP) scores were used to detect
canalizing genes [11]. The IMP score for gene Xi is defined as
∆ij,k = CoDXj ,Xk(Xi)−max(CoDXj(Xi), CoDXk(Xi)) (2.6)
where ∆ij,k is the increase in prediction power using two predictors over the maximum
of the two CoDs when using each predictor individually. The IMP score quantifies
the synergistic prediction effect of the pair. The definition is naturally extended to
more genes but we will not need that here. We define the canalizing power, tN(Xi)
of a gene Xi, relative to the tree model (G,Θ), by
tN(Xi) =
∑
1≤j<k≤N,j,k 6=i
∆ij,k (2.7)
The canalizing power measures the total increase in prediction power using pairs of
predictors over the maximum of the respective single predictors. As N grows, the
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Table VI. CPT of X2 and X3 given X1 in Fig. 8(b), with C1,0 = 0.5,
η12 = η13 = η = 0.5, and δ12 = δ13 = δ = 0.
P (X2 = 0, X3 = 0|X1 = 0) 0.25
P (X2 = 0, X3 = 1|X1 = 0) 0.25
P (X2 = 1, X3 = 0|X1 = 0) 0.25
P (X2 = 1, X3 = 1|X1 = 0) 0.25
P (X2 = 1, X3 = 1|X1 = 1) 1
canalizing power tN(Xi) will also grow. The canalizing power of a gene is quantified
by the extent of the synergistic prediction from all genes in the model.
To illustrate the above definition, we consider the 3-gene branch shown in Fig.
8(b). To facilitate intuition of Eq. (2.7), we assume that C1,0 = 0.5, η12 = η13 = η,
δ12 = δ13 = δ, and 0 ≤ δ ≤ η ≤ 0.5. Straightforward calculations yield t3(X1) =
δ2 − δ + η − η2, t3(X2) = 0 and t3(X3) = 0. For fixed cross-talk η, t3(X1) is a
parabola that is a decreasing function on δ ∈ [0, 0.5]. The maximum value is attained
when δ = 0 and max(t3(X1)) = 0.25 when η = 0.5. t3(X2) = t3(X3) = 0, since
P (X3|X1, X2) = P (X3|X1) and P (X2|X1, X3) = P (X2|X3), X1, X2 and X3 being
conditional independent from each other. Table VI gives the CPT of X2 and X3
given X1 when C1,0 = 0.5, η12 = η13 = η = 0.5, and δ12 = δ13 = δ = 0. It says
that when X1 is OFF, X2 and X3 will be equally likely to be in the states (0, 0),
(0, 1), (1, 0), and (1, 1); however, when X1 is ON, X2 and X3 can only be in the state
(1, 1), i.e., X1 has taken over the control of X2 and X3. This precisely describes the
properties of canalizing genes.
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2. Canalizing Power and Network Size
To see the effect of increasing the number of nodes in the network shown in the 3-gene
branch, let us consider the two possible ways of adding a new node to the branch
shown in Fig. 18. For parts (a) and (b), we have
tN(X1) =
∑
1<j<k6N
∆1j,k = tN−1(X1) +
∑
1<j<N
∆1j,N ,
and
tN(X1) =
∑
1<j<k6N
∆1j,k = tN−1(X1) + ∆
1
3,N .
respectively. In part (a), the newly added node XN is able to a form synergistic pair
with any node Xi, i = 2, 3, . . . , N − 1, whereas in part (b), the newly added node
XN can only form a synergistic pair with X3. Therefore, we expect to see that the
canalizing power of X1 is much higher in part (a) than the canalizing power of X1 in
part (b). Fig. 19 shows the canalizing power for X1 in Fig. 18(a) as a function of
network size. The power grows faster when there are large discrepancies between the
cross-talk and conditioning parameter. Fig. 20 shows the canalizing power for X1
in Fig. 18(b) as a function of network size. The canalizing power grows slowly and
eventually becomes saturated as N becomes larger.
X3
X1
X4
X2
XN
X2X1
X3
X4 XN
(a) (b)
Fig. 18. Adjoining a branch: (a) grow a node directly from X1; (b) grow a child directly
from X2.
41
2 4 6 8 10 12 14
0
2
4
6
8
10
12
14
16
18
20
Network Size N
Ca
na
liz
in
g 
po
we
r o
f X
1
 
 
η: 0.5, δ: 0
η: 0.5, δ: 0.1
η: 0.3, δ: 0.2
Fig. 19. Canalizing power for X1 in Fig. 18(a), with C1,0 = 0.5.
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Fig. 20. Canalizing power for X1 in Fig. 18(b), with C1,0 = 0.5.
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Fig. 21. Canalizing power for X1 in the 3-gene branch shown in Fig. 8(b), with
C1,0 = 0.5.
3. Canalizing Power and Network Parameters
The joint distribution of the 3-gene branch in Fig. 8(b) is determined by 5 parameters:
C1,0, η12, η13, δ12 and δ13. We can plot the canalizing power of X1 with respect to η12,
η13 (or any other two parameters) given the remaining 3 parameters. Fig. 21 shows
the canalizing power for X1 in the 3-gene branch shown in Fig. 8(b), with C1,0 = 0.5.
The intensity represents the canalizing power. The canalizing power decreases as the
conditioning parameter δ12 = δ13 = δ increases. The red square indicates the point
with the maximum canalizing power. Fig. 22 shows the canalizing power for X1 in
the 3-gene branch shown in Fig. 8(b), with δ12 = δ13 = 0. The maximum canalizing
power (red square) increases as C1,0 increases.
Fig. 23 is an enlargement of the last subfigure in Fig. 22. Let us focus on
the red square in Fig. 23, which corresponds to C1,0 = 0.9, δ12 = δ13 = 0 and
η12 = η13 = 0.111. Table VII shows that, given the status of X2 and X3, X1 is
highly predictable. In fact, Table VII resembles the Boolean function X1 = X2 ∧X3.
Therefore, X2 and X3 has high synergistic prediction power for X1.
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Fig. 22. Canalizing power for X1 in the 3-gene branch shown in Fig. 8(b), with
δ12 = δ13 = 0.
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Fig. 23. The last subfigure in Fig. 22. Red square: C1,0 = 0.9, δ12 = δ13 = 0 and
η12 = η13 = 0.111.
44
Table VII. CPT of X1 given X2 and X3 for the red square in Fig. 23.
P (X1 = 0|X2 = 0, X3 = 0) 1
P (X1 = 0|X2 = 0, X3 = 1) 1
P (X1 = 0|X2 = 1, X3 = 0) 1
P (X1 = 1|X2 = 1, X3 = 1) 0.9
It is important to distinguish between master genes and canalizing genes. In our
simulations, we see that both definitions tend to reward genes which control many
pathways; however, the two concepts are not the same. In fact, for a master gene Xi,
we evaluate it by all the possible pair-predictors formed by the rest of the genes in the
network. Hence, CoDD(Xi) is maximized when there is no cross-talk and conditioning
in the network and CoDD(Xi) = 1 in this case. On the other hand, for a canalizing
gene Xj, we evaluate it by all the possible synergistic pair-predictors formed by the
rest of the genes in the network. Thus, if there is no cross-talk and conditioning
in the network, tN(Xj) = 0. The reason is that single predictors have already given
perfect predictions for Xj and there is no room for improvement for double predictors.
Figs. 21 and 22 confirm this observation by showing that in all regions where cross-
talk and conditioning are 0, the canalizing powers are also zero. In sum, the master
gene definition measures the ability of control, whereas the canalizing gene definition
measures the ability of taking over control.
4. An Example of a DUSP1 Pathway
The example given in this section not only shows how the calculations of the canalizing
power defined in Eq. (2.7) can be performed on data obtained from a microarray
experiment but it also serves as a validation of the ability of the concept of canalizing
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power to quantify the known important biological role of some genes, i.e., DUSP1.
We focus on a pathway involving DUSP1 and Ras genes that are especially
important in melanoma tumors. The regulatory pathway presented on Fig. 24 is
constructed from canonical pathway knowledge. The dataset used to infer the model
parameters was obtained in a microarray experiment involving 31 melanoma patient
samples, 19 normal tissues and 12 from tissues diagnosed with melanoma. Gene
expressions were binarized to indicate change or no change relative to a reference
expression level for each gene individually. A change can be under- or over-expression.
Both cases are labeled as 1, whereas no significant change from the reference is labeled
as 0 [11].
When DUSP1 is OFF, or down-regulated, the downstream (relative to the de-
picted pathway) genes are controlled by the Ras oncogene through phosphorylation
(+p) and transcriptional activation (+Tr). When DUPS1 is ON, or up-regulated, it
de-phosphorylates ERK1/2, thereby overriding the signal sent by Ras. The biological
role of DUSP1 indicates that it is likely a canalizing gene that can take over control
of downstream genes when it is ON. Thus, we expect to capture its behavior by the
IMP score and the value of canalizing power as defined in the previous subsection.
To test whether DUSP1 shows high canalizing power, we have considered each gray
gene from Fig. 24 as a target and computed its respective canalizing power using
all possible triple predictors from the rest of the genes measured by the microarrays
along the pathway,
tN(Xi) =
∑
16j<k<l6N,j,k,l 6=i
∆ij,k,l,
where
∆ij,k,l = CoDXj ,Xk,Xl(Xi)−max(CoDXj(Xi), CoDXk(Xi), CoDXl(Xi)).
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The results are summarized in Table VIII. Note that DUSP1 significantly stands
out from the rest of the genes and the results agree with our knowledge about the
biological role of DUSP1.
F. Hypothesis Testing to Detect a “Cut” in the Pathway
Detecting structural changes in a regulatory pathway is critically important when
designing therapeutic strategies, e.g. how a drug affects gene regulation in a pathway?
CoD measures gene-gene interactions and therefore provides a means to detect a
structural change. In the setting of the tree model, a cut between the parent Xj and
the child Xi weakens the regulation of Xj on Xi. Fig. 25(a) shows an original tree
with a cut tree in Fig. 25(b), the cut occurring between the first and second nodes.
Given a cut between parent Xj and child Xi, Xi will be more susceptible to influence
from other genes and both the cross-talk ηji and the conditioning δji parameters
will increase. Zero cross-talk and conditioning indicate deterministic control and 0.5
cross-talk and conditioning indicate no control at all, i.e., given the status of Xj, Xi
is equally likely to be ON or OFF. A cut can be partial, meaning it increases the
cross-talk and conditioning parameters, but not necessarily to 0.5, or complete, in
which case they are increased to 0.5.
When a drug is applied with the intent of cutting the pathway between X1
and X2 as shown in Fig. 25(b), we would like to determine its effectiveness. This
determination corresponds to two competing hypotheses:
H0: There is no cut between the first and second nodes in the pathway (drug inef-
fective).
H1: There is a cut between the first and second nodes in the pathway (drug effective).
The corresponding quantitative hypothesis test is given by
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Fig. 24. DUSP1 network: +p indicates phosphorylation, -p indicates dephosphoryla-
tion, and +Tr indicates transcriptional activation. The gene expression levels
of the gray-colored nodes were measured in an experiment performed at the
Translational Genomics Research Institute (unpublished work). There was no
measurement of the gene expression levels for the white-colored nodes. Data
from experiments show that when turned ON, DUSP1 exerts strong control
over the downstream genes via de-phosphorylation of ERK1/2.
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Table VIII. Canalizing power for each gray-colored gene in Fig. 24. Canalizing power
of DUSP1 stands out from the rest. Only ∆ij,k,l ≥ 0.4 are considered when
computing canalizing power for each gene. Note that the order of the list
need not follow their topological order depicted on Fig. 24.
Gene Names tN(Xi)
DUSP1 13.4286
NDRG1 5.1
VEGF 5.0833
JUN 4.6667
CDKN1A 3.6667
IL6 2.6429
MYC 2.5385
IL8 1.7778
IGF1R 1.5
FOSL1 1.2
CCND1 0.9231
FOS 0.8667
PLAUR 0
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Fig. 25. Original tree (a) and the tree with a cut between the first and second node
(b).
H0: CoDS(X1) ≥ T
H1: CoDS(X1) < T
where the test statistic is the empirical-mean CoDs using all single predictors com-
puted from sample data. CoDS(X1) represents how strongly X1 is connected to other
nodes in the pathway.
To evaluate the hypothesis test we need the distribution of the test statistic
(empirical-mean CoD). Since we do not have an analytic form for the distribution,
as we would, let’s say, in the case of testing the mean of a Gaussian distribution, we
take Monte Carlo approach to generating the distribution. This requires sampling
from the pathway, for which we need to know the joint probability distribution of
the underlying Bayesian network. Once the JPD is known, it is straightforward to
sample from it. For example, in the case of Fig. 25(a), with C1,0 = 0.5, ηji = 0.1, and
δji = 0.1, 1 ≤ i < j ≤ 6, we can first generate K samples of X1, with P (X1 = 1) = 0.5,
and then generate X2 samples based on the probabilities P (X2 = 1|X1 = 0) = 0.1 and
P (X2 = 1|X1 = 1) = 0.9. In this fashion, we can generate K samples for all 6 nodes
in the tree and calculate the empirical mean CoDs using all single predictors from
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the K samples. Every time we generate K samples from the pathway, we will get a
different empirical mean CoD, thereby forming an empirical-mean CoD distribution.
T = CoDS(X1) is calculated when the null hypothesis is true. In the standard
way, this is done under the conservative assumption that CoDS(X1) = T . For ex-
ample, when C1,0 = 0.5, ηji = 0.1, and δji = 0.1, 1 ≤ i < j ≤ 6 in Fig. 25(a),
CoDS(X1) = 0.5949. T is a population parameter that represents our belief of the
status quo (drug ineffective).
Fig. 26 illustrates the empirical-mean CoD distribution using single predictors for
X1 under the null hypothesis (solid line), η12 = 0.1 and δ12 = 0.1, and under a specific
alternative hypothesis (dashed line), η12 = 0.2 and δ12 = 0.2, where the empirical
CoDs are calculated from 100 samples. The dashed line is shifted more towards
the left compared to the solid line, after the cut, the prediction of X1 from other
nodes in the tree is weakened. Under the null hypothesis, we calculate the critical
point for the 0.05 significance level to be 0.4882. Under the alternative hypothesis, we
calculate the corresponding type II error to be 0.2644. Since the type II error depends
on the specific parameter values assumed under the alternative, we can plot type II
errors as a function of the alternative values and produce the corresponding operating
characteristic curves [57]. These are shown Fig. 27 for sample sizes K = 50, 100,
and 200 respectively. Note that the type II errors decrease quickly with increasing
η12 and δ12 in all 3 cases. Also, the type II error is smaller for larger sample size K,
in other words, it is easier to detect the cut with larger sample size.
To apply the hypothesis test in practice, we first need to estimate the parameters
(cross-talk and conditioning parameters) of the pathway. We can take gene expression
data from N cell lines and estimate these parameters. Once the tree/pathway is
specified (therefore, its JPD), we can generate mean CoD histograms using the same
techniques described above. The goal is to generate mean CoD histograms when no
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Fig. 26. Empirical mean CoD (single predictor) distribution for X1 in Fig. 25, with
sample size K = 100. Solid line for: pathway in Fig. 25(a), with η12 = 0.1
and δ12 = 0.1; dashed line for pathway in Fig. 25(b), with η12 = 0.2 and
δ12 = 0.2. The critical point for 0.05 significance level is 0.4882 and Type II
error is 0.2644.
drug is applied. Now, we can apply the drug to M identical cell lines and measure
their gene expressions. We can then compute the empirical mean CoD (test statistic)
from the M samples. If this test statistic is very small and unlikely to happen under
the null distribution generated in the previous step, then, we can claim that the drug
is effective and quantify it by a p-value.
G. Conclusion
In this chapter we have modeled gene biological pathways in the context of Bayesian
networks whose DAGs are trees and examined the relations between CoDs and the tree
model extensively. Three regulatory issues have been addressed in this framework:
master genes, canalizing genes, and cutting pathways. Our interest in this problem
52
0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
δ12 and η12 under the alternative
Ty
pe
 II
 e
rro
rs
operating characteristic curve for X1
 
 
K = 50
K = 100
K = 200
Fig. 27. Operating characteristic curves for X1 in Fig. 25, with sample size K = 50,
100, and 200. Assuming C1,0 = 0.5, ηji = 0.1 and δji = 0.1, under the null
hypothesis.
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Fig. 28. Empirical mean CoD (single predictor) distribution for X1 in Fig. 25, with
a cut between X2 and x3 instead of X1 and X2. Sample size K = 100: solid
line for pathway before the cut, with η23 = 0.1 and δ23 = 0.1; dashed line for
pathway after the cut, with η23 = 0.2 and δ23 = 0.2. The critical point for the
0.05 significance level is 0.4882 and Type II error is 0.4858.
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stems from the manner in which regulation dysfunction leads to cancerous phenotypes
and our desire to better characterize and mitigate that dysfunction.
Although we have focused on the tree model, the ideas presented can be extended
to polytrees, where multiple parents may exist for the same node, albeit, with greater
complexity. For instance, Pearl’s algorithm can also be extended to compute the joint
distribution of any nodes in a polytree [58] and Rebane and Pearl have provided an
efficient algorithm to recover polytrees from data [59]. The difficulty is that a node in
the polytree with k parents requires 2k parameters to define the conditional probabil-
ity table (assuming binary data). Given the limited sample size in a typical genomic
experiment, it may be better to stay with simple trees rather than polytrees; how-
ever, when a sufficient sample size is available or prior knowledge strongly indicates
multiple parents, we may switch to the polytree model.
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CHAPTER III
IDENTIFYING MECHANISTIC SIMILARITIES IN DRUG RESPONSES
This chapter presents a time series data alignment algorithm to identify mechanistic
similarities in drug responses, which can facilitate the characterization the mecha-
nisms of action of cancer drugs. We first introduce the background information on
the Green Fluorescent Protein (GFP) technology and its usage toward tracking drug
responses over time. Then, the rationale of drug comparisons is discussed. Following
that, we develop the alignment algorithm in detail. Finally, its performance is tested
on a series of real drug experiments.
A. Using Green Fluorescent Protein Technology to Track Drug Responses
The ability to measure the abundance and degree of modification of many macro-
molecules in cells has allowed researchers to examine cells for particular, existing
molecular characteristics that indicate susceptibility to particular drugs [60–62]. This
approach has produced a number of very useful guidelines to the use of therapeutics;
however, it has failed in instances where the drug induces changes in the type and/or
abundance of proteins that either pump drugs out of the cell or proteins that allow
the drug-targeted activity to be provided in an alternative way that is not affected by
the drug [63,64]. For these reasons, the ability to examine the molecular dynamics of
cells’ responses to drugs becomes of primary interest. In addition, identifying those
dynamic patterns will help to detect if drugs targeting a particular gene produce or
not the desired response. One possible way to achieve this goal would be to develop
a way to quantitate the degree of similarity between the responses that cells show
when exposed to drugs, so that consistencies in the regulation of cellular response
processes that produce success or failure can be more readily identified.
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1. Analysis of Gene Transcription Dynamics
A considerable amount of research using fluorescent proteins as transcription activity
reporters has examined transcription in living cells in both single-cell and multicellular
organisms [65, 66]. Since fluorescent imaging can be carried out in ways that do not
destroy cells, fluorescent reporters are very effective tools when studying the time
evolution of gene expression. Inserting DNA cassettes with a particular promoter
driving expression of a fluorescent protein into egg cells or partially differentiated
intermediate cells in ways that allow the cassette to become incorporated in the cell’s
genome allows one to follow that cell and its daughter cells’ developmental course.
This kind of information can be used to specify in which cell types and in how
many cells a specific gene is active throughout the stepwise course of development
and provide clues to gene function. By using a very similar approach on cells with
reporters responding to drugs, it is possible to determine which and how many cells are
altering the transcription level of a given gene during the course of the cell population’s
response to the drug. As cells’ responses to drugs can take days to run their course,
it is expected that a drug that mobilizes a change in the transcriptional regulation of
a gene or genes in a cell will produce a distinguishable temporal trajectory of change
in both the level of transcriptional change in cells and the number of cells showing
altered expression level in a population of treated cells. It is further expected that sets
of drugs that induce the same or a very similar alteration in transcriptional regulation
will produce similar temporal trajectories, allowing them to be identified as having
similarities in their mechanisms of action (MOA).
In our adaptation of this methodology, imaging is carried out using a robotic
imaging device (ImageXpressMICRO, Molecular Devices). Multichannel imaging of
sets of adherent cells with various reporters cultured in 384 well plates can be carried
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out every hour, and at typical initial cell loading levels these cultures can be fol-
lowed for 50 hours. Two typical fluorescent images are shown in Figs. 29(a) and (b),
where nuclei are detected in the blue channel and promoter reporters are detected in
the green channel. The objective of image processing is to extract gene-expression
levels from the population of cells in the fluorescent image and follow these inten-
sity distributions over time. To do so, we utilize morphological image processing, in
particular, the watershed transformation [67]. While the image processing is rather
involved, overall it breaks down into three major components: nuclei channel seg-
mentation, reporter channel segmentation, and measurement of cell-by-cell promoter
activity levels. Briefly, to extract the promoter activity level for each cell, one needs
to first identify the position of cells in the image and then identify the area of the
image covered by each cell’s cytoplasm. As the cells can be either compact or spread
out, we estimate the promoter activity by measuring the sum of the green fluorescent
protein (GFP) intensity (arbitrary camera intensity units) in all the pixels within the
cell area and reporting the log2 transformed, summed intensity values for each cell.
To achieve this, we first process the nuclei (blue) channel to locate all nuclei present
in the image, and then process the reporter (green) channel to determine the activity
level of the reporter for each cell. We refer to [19] for full imaging details.
Live cell imaging analysis provides two distinct types of cell-by-cell information
that are not easily measured over long time spans by other means: (1) the extent of
change in promoter activity in the treated population relative to that of the untreated,
control population, and (2) the percentage of cells in the treated population shifted
into a position in the expression level distribution not occupied by the untreated
control population, as a consequence of drug activity. An example of how these two
measurements are calculated is presented in Fig. 29(c), where g(x) (control or pre-
drug case) and f(x) (post-drug case) represent the log2 GFP intensity distributions
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Fig. 29. Two typical fluorescent images for cell-line HCT116 with a promoter reporter
for the gene MKI67: (a) before any drug is applied (control or pre-drug case);
(b) 43 hours after the drug Lapatinib was added (post-drug case); (c) calcula-
tion of population shift/change and fold change: g(x) and f(x) represent the
log2 GFP intensity distributions for the cells in (a) and (b), respectively.
for the cells in Fig. 29(a) and (b), respectively. The percentage of population change
can be calculated by the difference in area between g(x) and f(x) (the gray area in Fig.
29(c)). Similarly, the fold change can be calculated as the mean difference between
the shifted cells and the control case. Note that when fold change is positive, the
corresponding population change will be denoted as positive, and when fold change
is negative, the corresponding population change will be denoted as negative.
2. What Information on Mechanistic Similarity Is Available in Drug Response
Trajectories?
In order to produce metrics of comparison for the similarity of transcription responses
induced by drugs, a model of how cellular responses to a drug will shape the trajec-
tories is required. A conceptual model (Fig. 30) of drug response by transcription
reporters in one molecularly homogeneous cell line responding to a series of drugs
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that target protein regulators acting on pathways of interest facilitates a simplified
consideration of the informational content of a trajectory. In this example we start
with a set of four genes (A, B, C, and D) that are suspected of contributing to the
regulation of a cellular process that we wish to inhibit. We know that a set of genes
(E, F , and G) are all strongly expressed when this process is operational and that
suppression of expression of gene G produces a reduction in cell proliferation, a de-
sired result of intervention, in these cells. We also have a series of drug compounds,
1, 2, 3, and 4, known to interfere in activation of the transcription factors B, A, D,
and C, respectively. In such a setting, Fig. 30(a), the important question to address
is if an examination of the dynamics of response to each drug by promoter reporters
for genes E, F , and G would produce sufficient understanding of the process mech-
anisms to determine which genes are driven by a similar regulatory mechanism? As
changes in the number of cells making a regulatory decision that leads to altered ex-
pression levels allows fairly intuitive interpretation of the dynamics, we will examine
this aspect of the conceptual model to illustrate the mechanistic characteristics of the
applied drugs that can be inferred through this approach.
If a technical replicate had been run, examining the effect of drug 2 on the gene
F reporter, we would expect the kind of trajectories labeled D2 and D2′ in Fig. 30(b).
(Levels of similarity for replicates in actual experiments are shown in figure on page
77.) If the cell line that these drugs are being tested on is molecularly homoge-
neous, repeated testing should produce very similar timings of when the cell line will
show detectable amount of population change, how rapidly the population change
trajectory increases, and how many cells respond to the drug eventually. These three
characteristics, time of onset of detectable transcription alteration, rate of population
change increase, and final percentage of responded cells define a dynamic population
response signature that can be systematically compared across a variety of drugs.
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Fig. 30. A variety of possible population change trajectories resulting from drug re-
sponses by the pathways diagrammed at the upper left side of the figure. Acti-
vation (A) and transcription (T) steps for which components are not shown in
this graph occur in the dashed connections between the transcription factors.
If two processes have no overlapping use of components, then the effects of drugs
targeting one of the processes should not produce a response from members of the
other process. The expected result for this situation is shown in Fig. 30(c). Drug 4
affects process 2 (gene C), but not process 1 (genes D, B and A), so drugs acting
on process 1 produce no effects on the process 2 reporter. Similarly, Fig. 30(d)
shows that all the three drugs acting on process 1 produce changes in the furthest
downstream reporter for process 1 and have no effect on the process 2 reporter.
When drugs are acting on different parts of the same process, it is possible that
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the dynamic signatures may be similar. The level of similarity may also vary be-
tween reporters placed at different locations along the process, due to differences in
both the time required and the step efficiencies in carrying out intervening activa-
tion/inactivation, transcription, and translation processes. Differences due to the
intrinsic properties of the drugs, rates of cellular uptake, eﬄux and enzymatic trans-
formation to an active form, where required, could also alter the dynamics of cell
response. In Fig. 30(b), responses are shown that could be seen if: (1) drug 2’s
action on gene B through an inactivation of a transcription factor, gene A, leads
directly to shutting down production of the reporter; (2) drug 1’s inactivation of
transcription factor gene B adds only a single additional transcription step to achieve
down-regulation of gene A; and (3) drug 3’s rate of inactivation of transcription factor
gene D is lower than that of drug 1 and 2 on genes A and B, but the inactivation is
very rapidly transmitted from gene D to gene B once achieved. These hypothetical
situations and results illustrate the general approaches that could be used to evalu-
ate how the key characteristics of population change relate to cellular drug response
dynamics.
B. Rationale for Drug Response Comparisons
To understand the mechanism of action (MOA) of a new drug, it is important to
compare its responses to a range of known drugs to see how similar they are. For
example, we often have standard drugs that can attack cell lines at various pathways,
e.g., survival pathways, proliferation pathways and apoptosis pathways, etc. Under-
standably, these various drugs will induce different response characteristics of the cell
line, which will then be reflected by the different GFP reporters. By comparing to
which existing drug the new drug has the most similar response, we can narrow down
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the possible MOAs of the new drug. Therefore, there is a need to design proper algo-
rithms that can match mechanistically similar regions for two responses. To design
such an algorithm, we first need to understand the nature of drug responses and the
types of biological information carried by the various response curves.
A population change responses curve usually has 3 different phases. First is the
dormancy period, where the population change is relatively constant and small. In
this period, the cell lines are usually making the necessary conditions ready for the
target GFP to show any effect. For example, if gene A regulates gene B, the GFP
response of B will not change until enough proteins of A have been made. Next
comes the responding period, where the right conditions have been prepared and
reporters start to be affected by the drug intervention. In this period, we usually see
an increase of the population change level. The speed of change depends on a number
of factors, including drug dosage. Finally comes the stabilizing period, where the drug
has reached its potential and population change is slowed down, eventually reaching
a certain level. The final proportion of changed cells depends on the overall efficacy of
the drug. An example of the 3 different periods is shown in Fig. 31(a). The reporters
start to actively respond to the treatment after ∼ 15 hours and reach a plateau after
∼ 32 hours. Note that the three steps described here do not necessarily happen for
every GFP reporter. For example, if the test drug is ineffective, then the treated cell
line will remain in the dormancy period without any significant population change.
The most informative region on any drug response curve is carried in the re-
sponding period described above, which is directly affected by a drug’s sensitivity
and efficacy. Here, we define the core response to be the part where population
change has attained a certain level (e.g. > 7.25% population change). We believe
that it is meaningful to study a drug’s MOA only if it is able to induce a sufficiently
population change at some time point during the whole experiment.
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To conceptually pose the drug response alignment problem, let us consider the
various cases shown in Fig. 31. In the simplest case shown by Fig. 31(a), if two
drugs have exactly the same chemical properties, then the response curves produced
by the same GFP reporter should look almost identical, as if they were technical
replicates. In this case, a direct alignment that matches the same time points on
the two responses together should suffice to capture the similarities between them
[Fig. 31(a)]. However, this is rarely the case in reality: (1) the slightly different
concentrations of the drugs or cell line conditions may cause the two identical drugs
to have different lengths of dormancy periods and therefore the responses will have
some delays [Fig. 31(b)]; (2) if the two drugs act on the same functional pathway,
the one hitting an upstream gene may show earlier responses that the one hitting a
downstream gene, again leading to different delays. In such cases, an alignment that
allows proper delays should be able to capture the overall similarity level between the
two responses [Fig. 31(b)].
A more interesting case is shown in Fig. 31(c), where the two responses show
different speeds in increase as well as the final percentage of recruited population per-
centage. As explained, such cases may be caused by the difference in drug sensitivity
and efficacy. The larger difference between the drugs, the quicker the responses de-
viate from each other. As shown in Fig. 31(c), the alignment will no longer continue
after ∼ 30 hours.
Another possible pair of responses is illustrated in Fig. 31(d), where the two
responses start similar and end similar, but they deviate from each other in the
middle portion for a short amount of time. Such cases may be caused by noisy
measurements, which break a longer contiguous alignment into two or more smaller
pieces.
Real experiments are more complicated and can be a mixture of the various cases
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Fig. 31. Conceptualized GFP responses on the population level. (a) Two almost iden-
tical responses. (b) Two responses with delays. (c) Two responses with dif-
ferent speeds and final population change levels. (d) Two similar responses
with a small portion of difference in the middle. The dashed lines indicate
the hypothetical threshold above which the responses can be considered as
the core.
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described above. Consider the drug experiment shown in Fig. 32, where cell line
HCT116 is subject to 3 different drug treatments: AG825, Lapatinib, and LY294002.
From a previous study [19], we know that both Lapatinib and LY294002 can attack
the autocrine loop involved with the ERBB2/3 heterodimer (higher efficacy for Lap-
atinib), thereby having very similar MOAs. On the other hand, AG825 mainly works
on ERBB2 alone and is not able to break the autocrine loop, thereby having a very
distinct MOA from the other two. Looking at the responses for TGFB1 in Fig. 32,
Lapatinib and LY294002 show quite similar behaviors on the population change di-
mension [Fig. 32(a)], with Lapatinib showing stronger responses with a faster speed
in the population change. Furthermore, on the fold change dimension, both Lap-
atinib and LY294002 show very similar overall shape/transition, with a small time
delay between the two, while AG825 shows some early similarity but with distinct
response after ∼ 10 hours.
The following descriptions summarize the key points that determine the mecha-
nistic similarity between two drug responses:
1. The most informative region on a drug response curve is contained in the core
region where enough population change has been recruited. The onset time
for the core region to happen may vary from drug to drug, however, once they
have started, they should proceed side by side. The longer time they continue,
the better mechanistic similarity between the two. Therefore, an important
criterion to determine the similarity between two drug responses is whether
there exists contiguous parts of signals that can be shared by the two responses
in their core regions.
2. The core region alignment may naturally extend to regions with lower popula-
tion change. In Fig. 31 (c), we see that the two drugs are quite similar until
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Fig. 32. TGFB1 responses to 3 different drugs on cell line HCT116. (a): population
change, (b): fold change. The curves are smoothed by a spline function with
10 degrees of freedom.
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∼ 30 hours. Whereas the core regions (defined by the 7.25% population change)
only have two pairs of points to be aligned, the total contiguous alignment really
starts from the very beginning. Therefore, it is more meaningful to consider the
longest contiguous alignment that contains the core region alignment. Here,
we define the core containing alignment to be the longest contiguous alignment
that contains at least one pair of points in the core region.
3. Noisy measurements can break an originally longer contiguous alignment into
several smaller pieces. Hence, we should allow small gaps around the core con-
taining alignment region described in point 2. In other words, the similarity
comparison for two drug responses should start from the core containing align-
ment and iteratively search its adjacent regions earlier or later in time, with a
small gap allowed (e.g. 2 hours) to account for noise. In the end, the different
sections should be aggregated together to reflect overall similarity level. Fig.
31(d) shows an example of such cases.
4. Due to the 2-dimensional nature of the drug response data (population change
and fold change), similarity requires the responses to be close on both dimen-
sions. However, in reality, we often observe that when population change is
small, the variation of fold change is quite large. Since the calculation of fold
change is based on the average behavior of shifted populations, the results might
be unreliable when there is only a small population shift. From a previous study,
we know that fold change difference can be confidently detected (p-value = 0.05)
when the population change is more than 7.25% [19]. Hence, we will only con-
sider the constraint on fold change dimension when the population change has
reached 7.25%.
To capture the similarities between reporter responses, we need an “intelligent”
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algorithm that is robust to noise, robust to time delays, and finally is able to find
all the contiguous parts of signals centered about the core mechanism. Directly
comparing points on the two signals is unrealistic, since it cannot handle delays
and speed variations on the time axis, as shown in Fig. 33(a). A popular set of
algorithms for time series alignment is called the Dynamic Time Warping (DTW)
method. It is based on the concept that the similarity between two time series should
be computed by locally deforming the time axis in order to minimize the cumulative
difference between the aligned points. The DTW algorithm was originally introduced
by Sakoe and Chiba for spoken word recognition [22] and it was applied to many
other fields including time series gene expression data comparisons [23]. However,
there are several disadvantages for the DTW type algorithms. First, for global DTW,
all the points on one signal must be mapped to points on the other signal. Thus,
outliers cannot be skipped and they can severely distort the alignment. Even though
efforts have been made to relax the global alignment constraint, e.g., the open-end
DTW algorithms [68], where the head or the tail sections can be left unaligned, are
incapable of skipping middle portion outliers if present in the signal. Second, DTW
algorithms tend to have many-to-one mappings for the alignment. Therefore, when
the two signals are different in amplitude, it is often the case that a large portion
of one signal will be mapped to a single point on the other signal to minimize the
overall cumulative distance between the two. A global DTW alignment is shown in
Fig. 33(b), as shown in the black box, 6 points on the green curve are mapped to the
same point on the orange curve, making the alignment very counterintuitive.
A better solution is shown in Fig. 33(c), where the two signals are aligned based
on the concept of Longest Common Substring (LCSS), which belongs to the class of
edit distance problems [69, 70]. LCSS finds the longest string that is a substring of
two or more strings. The concept can be extended to real-valued signals in a recursive
68
Fig. 33. Direct alignment. It completely ignores the variation in time axis. (b) Global
DTW alignment. Many superfluous and spurious matches are seen at the
ending sections. (c) RLCSS algorithm. Only one-to-one mapping is allowed
and small gaps are allowed to account for noisy measurement.
fashion (the RLCSS algorithm), as we will explain in latter sections. The benefit of
RLCSS is that the aligned signals are contiguous and only one-to-one mapping is
allowed, which satisfies our assumptions of biological similarity. Furthermore, small
gaps (2 hours) are allowed between different sections to account for noisy measure-
ments.
C. Recursive Longest Common Substring Algorithm
1. Definition of Longest Common Substring (LCSS) on Time Series
The original LCSS model refers to a 1D sequence with discrete values, i.e., strings.
For example, the sequences ABAB and BABB have their LCSS to be BAB. Our data
is 2-dimensional and real-valued. The first dimension is population change and the
second is fold change. These reflect two important aspects of the same cell population
over time. Therefore, it is natural to consider both dimensions simultaneously when
defining similarities.
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Formally, letA = ((ax,1, ay,1), . . . , (ax,m, ay,m)) andB = ((bx,1, by,1), . . . , (bx,n, by,n))
be two drug responses, where x is the dimension for population change, y is the
dimension for fold change, m is the length of A, and n is the length of B. Let
A[1, . . . , i] = ((ax,1, ay,1), . . . , (ax,i, ay,i)).
Definition 1. Given an integer δ, a real value k ∈ [0, 1] and a pair of nonnegative
real values ε = (ε1, ε2), we define the length of the longest common substring (LCSS)
between the two dimensional time series A and B to be the largest element in matrix
Rδ,ε, where the element Rδ,ε[i, j] is defined by:
Rδ,ε[i, j] =

0 if i = 0 or j = 0
1 +Rδ,ε[i− 1, j − 1] if |ax,i − bx,j| ≤ ε1, |ay,i − by,j| ≤ ε2, |i− j| ≤ δ,
|ax,i| ≥ k and |bx,j| ≥ k,
or if |ax,i − bx,j| ≤ ε1, |i− j| ≤ δ,
and |ax,i| ≤ k or |bx,j| ≤ k,
0 otherwise
where the constant δ controls the flexibility of matching in time and the constant
vector ε controls the matching threshold and k determines the population change
threshold above which fold change constraint will be applied (i.e., the population
threshold for the core mechanism). Throughout the paper, we will set k = 0.0725,
because fold change difference can be confidently detected (p-value = 0.05) when
population change has reached 7.25% [19]. Intrinsic to Definition 1 is that Rδ,ε[i, j]
depends only on the previous diagonal element and the current element-wise distance.
Hence, Rδ,ε[m,n] can be efficiently found by filling the tabular starting from Rδ,ε[0, 0].
After the table has been filled, the actual common substring can be found by going
back diagonal-wise from the largest entry in the table until a 0 entry is reached
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Table IX. The dynamic programming table for finding the LCSS of two 1-D se-
quences [0.2, 0.1, 0.1, 0.2] and [0.1, 0.2, 0.1, 0.1], with the parameters set to
be: δ = 4, k = 0, ε = ε1 = 0. The trace-back path is highlighted in bold
face and it contains time indices: {(1, 2), (2, 3), (3, 4)}
0.1 0.2 0.1 0.1
0 0 0 0 0
0.2 0 0 1 0 1
0.1 0 1 0 2 0
0.1 0 0 2 0 3
0.2 0 0 1 0 1
(the trace-back path shown in Table IX). Intuitively, Definition 1 says that 2 drug
responses are similar if either of the two conditions satisfies: (1) if population change
is large enough, both dimensions have to be similar simultaneously; (2) if population
change is not large enough, only population change has to be similar, because the
measurement on fold change is no longer reliable. The requirement is made to be
consistent with condition 4 described in Section B of this chapter. For illustrative
purposes, a numerical example for the LCSS is shown in Table IX. The same operation
can be readily extended to real valued sequences as illustrated in Definition 1.
By definition, the substring must be contiguous. This differs from the concept
of longest common subsequence, where the subsequence is not necessarily contiguous
(for example, the longest common subsequence between ABACD and BABD is BAD
or ABD). Furthermore, different choices of δ and ε will lead to different alignment
results. A small δ will restrict the alignment points to be close in time. In fact, δ = 0
degenerates to the calculation of direct matching [Fig. 33(a)]. For ε, a very small
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threshold will lead to almost no alignment between the two signals, whereas a very
loose threshold will lead to every pair of points being aligned as similar. Therefore,
an appropriate choice of δ and ε is important for the application of LCSS alignments.
A good choice of the two values depends on the application. Thus, we will have a
detailed discussion in the results section.
2. Recursive LCSS Algorithm (RLCSS)
The LCSS algorithm described in the previous section is not yet sufficient for drug
response comparisons. First, there is no guarantee that the longest common substring
will intersect with the region where sufficient population change has been reached and,
therefore, cannot be called the core mechanism described in Section B. Second, even
if the core mechanism is found, small gaps should be allowed around it to compensate
for noisy measurements. For these two reasons, we define an algorithm that will
utilize the LCSS concept recursively to identify the core containing alignment as well
as its surrounding pieces. (Note that the trace-back path contains the matched time
indices from the two sequences and, therefore, the actual matched points on the two
sequences can be directly read out from the path).
1. For a pair of two dimensional sequences A and B, fill the dynamic program-
ming (DP) table as described in Definition 1. Find the longest trace-back path
(ending with the largest element in the DP table). If its corresponding matched
points contain any member that has sufficient population change on both se-
quences (≥ 7.25%), then record the trace-back path; otherwise, keep searching
the second longest trace-back path in the DP table until it satisfies the popula-
tion change threshold requirement. Denote the track-back path to be T , where
(p, q) is the pair of starting time indices and (s, t) is the pair of ending indices.
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Stop and go to step 2. If no such trace-back path exists, exit the program and
return T = NULL.
2. For the head section sequences A[1, . . . , p − 1] and B[1, . . . , q − 1] of A and
B, respectively, fill the DP table to find the LCSS path of the truncated head
section sequences. If the ending indices of the LCSS trace-back path is within
the time gap allowed from (p, q), then add the newly found trace-back path
to the beginning of T ; otherwise, continue to search for the second longest
common substring until it meets the time gap constraint. Update (p, q) so that
it represents the starting indices of the newly formed T and go to step 3. If no
such trace-back path is found, stop and continue to step 4.
3. Repeat step 2 for the remaining head sections of A and B until no trace-back
path satisfies the condition described in step 2. Stop and continue to step 4.
4. For the tail section sequences A[s + 1, . . . ,m] and B[t + 1, . . . , n] of A and B,
respectively, fill the DP table to find the LCSS path of the truncated tail section
sequences. If the starting indices of the LCSS trace-back path is within the time
gap allowed from (s, t), then add the newly found trace-back path to the end of
T ; otherwise, continue to search for the second longest common substring until
it meets the time gap constraint. Update (s, t) so that it represents the ending
indices of the newly formed T , and go to step 5. If no such trace-back path is
found, stop and exit program.
5. Repeat step 4 for the remaining tail sections of A and B until no trace-back
path satisfies the condition described in step 4. Stop and exit program.
Note that by aligning the head sections and tail sections separately, it is guaran-
teed that the time order will not be destroyed. Fig. 34 shows a graphic illustration
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of the RLCSS algorithm.
Definition 2. The similarity Sδ,ε(A,B) expressed in terms of the RLCSS similarity
between the time series A and B is given by:
Sδ,ε(A,B) =
|T |
min(n,m)
where T is found by the RLCSS algorithm and |T | is the cardinality of T . Note that
Sδ,ε(A,B) is always between 0 and 1 – the larger the value, the greater the similarity.
Fig. 34. Illustration of the RLCSS algorithm. The DP table is represented by the big
solid black box. The algorithm starts by finding the core containing align-
ment (red solid path), and subsequently recursively finds the head section
alignments and tail section alignments (orange and green paths) around it
with small time gap allowed (dashed boxes). In the end, the alignment path
will include all the 5 sections.
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D. Results for RLCSS Alignment
In this section, we apply the RLCSS algorithm to drug response data. To test its
performance, we need to know a priori the MOA of the testing drugs and see whether
the alignment results agree with our prior knowledge. For instance, if we know that
drug X and Y have very similar effects on some cell line (due to similar MOAs),
can the proposed RLCSS algorithm also capture their similarities and claim they are
similar? Conversely, if drug X and Z are very different in their MOAs, is the RLCSS
algorithm also able to claim that they are dissimilar?
To test the performance of the proposed RLCSS algorithm, we consider the re-
sults of a study in which the detailed MOA of each drug has been carried out [19]. In
this study, 5 drugs (Lapatinib, LY294002, Temsirolimus, U0126, AG1024) are tested
against the cancer cell line HCT116. Referring to Fig. 35 and ranking drug respon-
siveness across the drugs for HCT116, one observes responses over most reporters but
with decreasing percentages of cells shifted for Lapatinib (EGFR/ERBB2), LY29004
(PI3K) and Temsirolimus (mTOR). This similarity of action with decreasing efficacy
falls directly along a survival signaling pathway headed by an activated receptor het-
erodimer, ERBB2/ERBB3, and then proceeds along the canonical PI3K/AKT/mTOR
pathway. The remaining drugs’ inhibitory powers would be ranked U0126 (MEK1/2)
and AG1024 (IGF1R) – AG1024 not shown in the figure because it acts on a kinase
not shown in the figure. All of these second tier drugs deliver very low reductions
of transcription of MKI67, the current “gold standard” [71, 72] in tumor pathology
for determining the proliferative state of a tumor. The results show that Lapatinib,
LY294002 and Temsirolimus have similar MOAs in the sense that they all target the
same survival pathways. On the other hand, U0126 and AG1024 have very dissimilar
MOAs compared to the three previously mentioned drugs.
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Fig. 35. Relative strengths of drugs versus position in pathways and inferred crosstalk
between survival and proliferative signal channels.
We design several sets of experiments to test if the proposed RLCSS algorithm
reaches the same conclusions as just described. First, to get a sense of the variation
presented in the drug response data, we test RLCSS on a set of technical replicates
(TR), with the idea that TRs should exhibit high degrees of similarity among each
other. Furthermore, by studying the TRs, we can to find a proper range for the
two key parameters in the RLCSS algorithm. Second, we test RLCSS on Lapatinib,
LY294002 and Temsirolimus, since they are related in their MOAs, and the degree of
similarity should be high, but not as high as with the TRs. Last, we test RLCSS on
Lapatinib, LY294002, U0126 and AG825, because the first two drugs are very different
from the last two in their MOAs. We set the parameter k = 0.0725 in Definition 1
and the time gap to be 2 hours for all experiments.
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1. RLCSS Performance on Technical Replicates
For RLCSS to work in practice, a proper set of values must be determined for δ
and ε = (ε1, ε2). δ controls the maximum time delay allowed for the matching. In
practice, the experiment lasts around 30− 50 hours and we know that transcription
is a relatively slow process. It usually takes about 8 − 12 hours for a reporter to
show some activity after the initial treatment. Therefore, in our application, we set
δ to be between 8 − 12 hours, which should be enough to compensate for the time
delays of different drugs. Moreover, we observe that RLCSS is usually insensitive to
δ variations in the sense that changing δ in that range does not change the alignment
results significantly (See Table X). ε determines the threshold for similarity. The idea
for determining ε is to set it to be large enough to compensate for the discrepancies
in technical replicates. Here, we set ε to be the value so that the worst case technical
replicates similarity is at least 75% (Fig. 36, black and red curves). In practice, we
have found that it is enough to account for the biological variations with ε1 close to
0.09 and ε2 close to 0.8, as we show in Table X.
Figs. 36(a) and (b) show a set of 4 technical replicates on the reporter MKI67
on the cell line HCT116 after treatment with Lapatinib, and Figs. 36(c) and (d)
show the RLCSS alignment for the worst case TR similarity. The pairwise alignment
result is summarized in Table X. The alignment results are not affected at all by the
different choices of δ ranging from 10 hours to 12 hours for all the pairwise alignments
except dup1 and 4, indicating that the RLCSS algorithm is very robust to δ variations.
As seen in Fig. 36 (d), the RLCSS algorithm successfully identifies the time delays
between the two replicates.
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Fig. 36. Technical replicates of Lapatinib treatment on cell line HCT116. ε is set to
be the value so that the worst case technical replicates (black and yellow)
similarity is at least 75%.
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Table X. Pairwise similarity between technical replicates, with different δ. As can be
seen, the different choices of δ do not affect the alignment results significantly.
Dup1, 2 Dup1, 3 Dup1, 4 Dup2, 3 Dup2, 4 Dup3, 4 δ ε
Similarity 1 0.917 0.667 0.958 0.75 1 8 (0.09,0.8)
Similarity 1 0.917 0.688 0.958 0.771 1 9 (0.09,0.8)
Similarity 1 0.917 0.708 0.958 0.792 1 10 (0.09,0.8)
Similarity 1 0.917 0.75 0.958 0.792 1 11 (0.09,0.8)
Similarity 1 0.917 0.75 0.958 0.792 1 12 (0.09,0.8)
Table XI. Pairwise similarity between 3 drugs with similar MOAs, with δ = 11 and
ε = (0.09, 0.8).
Lapatinib Lapatinib LY294002
LY294002 Temsirolimus Temsirolimus
TGFB1 0.862 0 0.138
ERBB3 0.862 0.724 0.793
EGR1 0.611 0.167 1
MKI67 0.621 0.69 0.897
FOS 0.677 0.583 0.25
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2. RLCSS Performance on Lapatinib, LY294002 and Temsirolimus
We design the second set of experiment to show the utility of RLCSS on 3 drugs
with similar MOAs. As described in Section B, it is meaningless to compare drug
responses on reporters whose responses have not changed enough during the whole
experimental span. Therefore, we select the reporters whose responses show at least
7.25% population change for at least 2 out of the 3 drugs. The similarity comparison
table of the 3 is summarized in Table XI. The 3 drugs show considerable amount of
similarity with each other, especially on ERBB3 and MKI67, the two key reporters
that reflect the MOA of drugs on cell line HCT116 [19]. We also observe that Lapa-
tinib is closer to LY294002 than it is to Temsirolimus. The result is also consistent
with our prior knowledge that LY294002 is closer to Lapatinib than Temsirolimus in
their actual positions of attack (Fig. 35).
3. RLCSS Performance on Lapatinib, U0126 and AG1024
The third set of experiments is intended to test whether the RLCSS algorithm is able
to detect mechanistic difference between drugs. As we know from earlier discussion,
Lapatinib is very different from U0126 or AG1024 in their MOAs. The similarity
results of the 3 drugs are summarized in Table XII. Ranking by the closeness to
Lapatinib, the order of similarity is: U0126 and AG1024.
4. RLCSS to Detect Apoptosis
It is possible that the reporter responses are different in the beginning, but later
in time behave similar due to a common process, e.g. apoptosis. This is because
once a cell has determined to go through apoptosis, all the reporters will have a
significant drop in their activity level and eventually die out. UNBS1415 is a drug,
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Fig. 37. Responses of ERBB3 to 5 different drugs. Looking at the figure, it is not sur-
prising to see why Lapatinib has 0 similarities with AG1024. For example, the
black curve (AG1024) has a very small population change during the entire
experiment and therefore it forms no core mechanism alignment with Lapa-
tinib, even though its early population change is quite close to Lapatinib. The
RLCSS algorithm has the advantage to filter out “uninteresting” similarities.
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Table XII. Pairwise similarity between 3 drugs with distinct MOAs, with δ = 11 and
ε = (0.09, 0.8).
Lapatinib Lapatinib U0126
U0126 AG1024 AG1024
TGFB1 0.793 0 0
ERBB3 0 0 0
EGR1 0.306 0 0
MKI67 0 0 0
FOS 0.583 0.611 0.861
that induces apoptosis on the cell line A549. In Figs. 38(a) and (b), we can see that
the initial responses are quite different for different reporters; however, later in time,
all responses seem to converge to the same behavior after 25 − 30 hours. In Figs.
38(c) and (d), we see that RLCSS algorithm successfully identifies the similarity later
in time, which is exactly what we expect. In fact, RLCSS algorithm is able to detect
all the similarities later in time for all pairs of responses in this example. For space
considerations, we only show one example here.
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Fig. 38. Responses of 8 reporters to the drug UNBS1450 on cell line A549. Note
that UNBS1450 is able to induce apoptosis on this particular cell line and
therefore, all the later responses are very similar for all the reporters. The
RLCSS algorithm successfully identified the similarity later in time. The
parameters are δ = 11 and ε = (0.09, 0.8).
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CHAPTER IV
MODELING POPULATION OF CELLS’ GENE EXPRESSION DYNAMICS
AFTER DRUG TREATMENT
This chapter presents a Markov model to describe a population of cells’ behavior after
drug treatment. To begin with, we introduce the asynchronous and independent
nature of cells’ responses to drug treatment. Then, we propose and develop the
Markov model in detail. The estimation of model parameters are also discussed. In
the end, we explain how to use the model for experimental design.
A. Gene Expression Varies from Cell to Cell
Since gene expression happens within individual cells and the traditional way of mi-
croarray experimentation measures average gene expression from a mixture of cells,
the results may not be reflective of the true state of gene activities. In fact, many
recent research findings note the limitations of a notion such as “average cell” be-
cause there is significant variation among different cells – even for the same cell line
in a hypothetically constant and homogeneous intracellular environment [73,74]. One
possible contributing factor is the inherent randomness associated with transcription,
e.g. chromatin remodeling. In particular, gene expression is governed by “transcrip-
tion bursts”: a gene stays a long time in the inactive state, followed by a short period
of activity where it makes a burst of transcripts [74]. Because such bursts happen
randomly within different cells, the number of transcripts also varies from cell to cell.
Given the inherent randomness associated with gene expression among differ-
ent cells, it is preferable to study the gene expression distribution instead of some
average value. One apparent benefit is that it can reveal subpopulation differences
(if any) to external stimuli (e.g. drugs), which is a key step in understanding cell
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dynamical response to drug treatments. Recently, [19] described an automated sys-
tem that allows researchers to track the transcriptional activities of multiple genes
under different external stimuli for extended periods. Briefly, the coding sequence
of a Green Fluorescent Protein (GFP) is fused with the promoter region of a gene
of interest. Subsequently, a single cassette bearing the promoter/GFP is delivered
into the genome of each cell in a population of cells (note that the insertion point of
the cassette is highly random among different cells). Any change in the expression
levels of the native coding sequence driven by that promoter will be reflected by the
intensity of the GFP reporter. The activity of the GFP reporter is captured by digital
microscopes at hourly intervals for ∼ 50 hours. Two typical snapshots of the GFP
images are shown in Fig. 39, parts (a) and (b). In the end, image processing algo-
rithms segment GFP intensity for individual cells and the gene expression for the cell
population is reflected by the intensity distributions of the respective GFP reporters
(Fig. 39(c)). Interested readers should refer to [19] for a detailed description for the
experimental protocols and image processing algorithms.
Two features can be observed from Fig. 39(c). First, the GFP intensity distribu-
tion appears bimodal after drug treatment rather than gradually moving to the left
as a unimodal distribution. This indicates that each cell make a large shift in its tran-
scription level independently of other cells rather than incrementally decreasing its
transcription level in synchronization with other cells. This suggests that a two-state
model could be used to describe the underlying gene expression activities. Second,
within each state, the actual transcription level varies from cell to cell (otherwise, the
gene expression would be two narrow spikes instead of two relatively wide bell shape
curves). The randomness could be attributed to the inherent variations caused by
“transcription burst” and to the different transcriptional efficiencies resulting from
the random insertions of the promoter/GFP cassettes into different cells.
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Fig. 39. Fluorescent images of the same imaging site for cell line HCT116 with a
promoter reporter for the gene MKI67 taken (a) before any drug was applied,
(b) 43 hours after the drug Lapatinib was applied (Green color indicates the
activity of GFP reporter and blue indicates the location of nuclei ). (c), the
GFP log2 intensity distributions for the same cell line at various time points
(time is color coded starting from red, changing to yellow and green and finally
blue).
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Fig. 40. Measuring the relative transcription activity difference through pop-shift and
fold-change. The gray area under the red distribution represents the shifted
cell population percentage compared to the blue distribution. The difference
between the mean of gray area and blue area is the corresponding fold-change.
(b) Bar-plots show the relative transcription activity of the cell population of
Fig. 39(c) throughout the experiment with the control population set to the
un-drugged population at the same time point. The drug was added after
5th hour. The top bar-plots show the pop-shift, while the bottom ones show
the fold-change. Each tick in y-axis of PS plots corresponds to 10% shift,
while each tick in fold change corresponds to a 2-fold concentration change
from previous tick. The green bars indicate up-regulation while the red bars
indicate down-regulation. The expression level of the initial state for both
case and control are shown at the left of each plot.
Given the time course gene expression distributions shown in Fig. 39(c), it
is possible to compute two types of measurements that describe their dynamics in
a concise way: the population-shift (PS) and fold-change (FC) (Fig. 40(a)). PS
describes the percentage of shifted cells relative to control (un-drugged case) at any
given time, and FC describes the extent of gene expression change of the shifted cells.
These two values can be plotted over time to reflect cell changes due to external
stimuli (Fig. 40(b)).
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B. Modeling the Gene-Expression Distribution of a Cell Population
Mathematical models facilitate systematic understanding of the gene-expression dis-
tribution data generated by the GFP technology. A good model should possess the
following properties:
1. It should be able to emulate the two-state asynchronous transition of individual
cells, while allowing for gene expression uncertainty.
2. It should contain biological relevant parameters essential to the observed process
and there should be a procedure describing how the model parameters can be
inferred from experimental data.
3. It should be capable of generating useful hypotheses for future experimental
design.
1. A Two-State Random Process to Describe Single Cell Behavior
As observed in experiments, a cell makes its decision asynchronously and indepen-
dently of the other cells. Therefore, in a homogeneous cell line, it suffices to assume
that the cells are i.i.d. The population behavior will be determined by the combina-
tion of the dynamics of each single cell, just as the number of heads in an experiment
of flipping coins from a pool of i.i.d. coins is determined by the individual coin’s
probability of landing head. We first consider the key parameters that describe the
gene-expression distribution for a population of cells:
1. Total number of cells: N .
2. Mean and Variance of the initial intensity distribution (State 1): µ1, σ1.
3. Mean and Variance of the post-drug intensity distribution (State 0): µ0, σ0.
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4. Rate of transition from state 1 to state 0 (or equally, the transition probability):
c.
5. Final proportion of responded cells: K.
6. The onset response time for each cell: t0.
The total number of cells N is determined by the experimental set-up. In a
typical GFP study, it is usually 300 − 400 cells. The means and variances of each
state are determined by the inherent randomness described in the introduction section
and are usually different from gene to gene. The rate of transition could depend on
the concentration/dosage of the drug applied to the cell line. Presumably, cells will
transition at a lower rate when lower dosage is used (but the dependency might not be
linear). The final proportion of responding cells measures the overall efficacy of that
drug and is directly related to the rate of transition. Finally, the onset response time
for each cell is defined to be the time needed for the cytoplasmic concentration of a
drug to reach a threshold level so that the drug can actually take effect. Note that the
exact level of the threshold is not important for our consideration and that the onset
time really reflects the fact that, upon adding the drug, it takes certain amount of time
for the drug to permeate the cell membrane and accumulate enough so that the cell
will actually be affected. The onset time could be different for cells in a homogeneous
cell line, because each cell is subject to different micro-environments, such as the
nutrients to which it is exposed and the cell cycle state it is in. Therefore, the onset
times of different cells reflect the “readiness” of particular cells to be transformed by
the drug.
Consider any single cell, for gene i, at time t, its expression value, ri(t) ∈ R,
is a real number and its expression state, xi(t) ∈ {0, 1}, is assumed to be binary
(the subsequent theory extending to any discrete state space). Note that the time
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Fig. 41. Schematic figures showing the key parameters that determine the dynamics of
gene expression distributions: Means and variances of state 1 and 0, transition
rate, and final proportion of responded cells.
t is not continuous in our experiment. It is discretized to reflect the sampling rate
when the GFP images are taken by the digital microscope: t = 0, 1, . . . , T , where T
is the duration time of the experiment. Whenever it is clear from the context, we
omit the time dependency. The expression value is governed by the expression state
and assumed to be randomly sampled from a Gaussian distribution whose mean and
variance are time invariant and are only determined by the corresponding expression
state of that gene i: ri(t) ∼ N(µxi , σxi). Denote pi0 = P (xi = 0) and pi1 = P (xi = 1)
and pi = [pi0, p
i
1].
Drugs act as external inputs for the cell and can break a cell’s hemostasis balance
by blocking/inducing the expression of the respective target gene(s). To model drug
effectiveness, we assume that the drug effect on its target gene i is either ineffective
or effective, namely yi(t) ∈ {0, 1}. When yi = 0, the respective target gene remains
in its original hemostasis balance state; when yi = 1, that balance is disturbed, which
leads to a new transition period, and possibly a new hemostasis state. Similarly, a
gene j not directly affected by the drug but affected through signaling cascades will
respond to its transcription factors’ net effect. In either case, for any gene in the
90
cell, yi can be viewed as the net effect of its regulators. Hence, we will call yi the
regulation state of gene i. A gene’s regulation state should affect its expression state,
as we explain next.
Here, we propose a two-state Markov model to describe the ith gene expression-
state dynamics with respect to its regulation state (net effect of drug or transcription
factors), yi. Let Ai,yi be the transition probability matrix of gene i with regulation
state yi:
Ai,yi =
 ai,yi00 ai,yi01
ai,yi10 a
i,yi
11
 (4.1)
where ai,yimn is the transition probability of gene i transition from the expression state
m to expression state n, with regulation state yi. We have a
i,yi
00 + a
i,yi
01 = 1 and
ai,yi10 + a
i,yi
11 = 1. Fig. 42 illustrates the two-state model proposed. Note that, given
yi, we implicitly assume that Ai,yi is time invariant, however, in a more general case,
Ai,yi can also be time dependent.
To update the expression state of gene i, we have:
pi(t+ 1) = pi(t)Ai,yi(t)=01yi(t)=0 + p
i(t)Ai,yi(t)=11yi(t)=1 (4.2)
where 1yi(t)=0 or 1yi(t)=1 is the indicator function. Eq. (4.2) says that, in any cell, the
expression state xi(t+1) of gene i at time t+1 is determined by its previous expression
state xi(t) and regulation state yi(t), through the corresponding transition probability
matrix Ai,yi . Note that the regulation state yi(t) is not necessarily Markovian and it
only reflects the net effect of the regulators of gene i. We subsequently return to the
discussion of yi(t).
The model proposed here describes the experimental observations that, for a
gene to change its expression state, all necessary conditions must already be in place,
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Fig. 42. Two-state Markov model to describe a gene i’s gene expression dynamics with
respect to its regulation state yi = 0 or 1. Note that the gene expression state
transition probabilities depend on the regulation state of that gene.
i.e., yi = 1. Upon such conditions, the gene will switch its expression state proba-
bilistically.
2. Constant Onset Time for Each Cell in the Cell Population
Let us consider the relationship that a drug inhibits the expression of gene i. In the
simplest condition, we can assume that the onset time for each cell t0 is a constant.
Furthermore, experiments suggests [19] that prior to adding drugs, the cells in a
particular cell line often show a unimodal gene expression distribution (see the thick
red curve in Fig. 39 (c)), indicating that all cells are in the same expression state.
Therefore, in our model we assume pi0 = 0 and p
i
1 = 1 to be the initial probability
distribution of the respective gene expression state. That is, all cells are concentrated
in the high expression state, xi(t) = 1, for any t ≤ t0. During that period, there is
a negligible likelihood, i.e., 0, probability, for transitioning from the high-expression
state to the low-expression state. Hence, ai,010 = 0 and a
i,0
01 = 0. After the onset
time t0, drugs start to take effect yi = 1, and therefore cells begin to transform from
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Fig. 43. A simplified two-state transition model, assuming identical onset time t0 for
each cell. (a) Before the onset time, all the cells stay in the high expression
state, with no probability of transition to the low expression state. (b) After
the onset time, with constant probability c, a cell will transit from the high
expression state to the low expression state.
high-expression state to low-expression state, with a constant transition probability,
ai,110 = c. On the other hand, once a cell has made its transition, it will stay at the
low-expression state with null probability of returning back, i.e., ai,101 = 0, as suggested
by the experimental data. The summary figure of these conditions is illustrated in
Fig. 43.
Given this simplified state transition model, it is interesting to compare theo-
retically derived results with data from experiments. Fig. 44 shows an example of
the simulation results generated from the transition model described in Fig. 43, with
N = 400, T = 20, µ1 = 15, σ1 = 2, µ0 = 8, σ0 = 2, t0 = 5, c = 0.2. Looking at Fig. 44,
we see that there is no population shift before the onset time t0 = 5, since we have
assumed ai,010 = 0. However, there is one apparent discrepancy between the simulation
results and the experimental results, namely, the number of transformed cells per
unit time is highest right after the onset time and gradually decreases as time goes
on. Such behavior is not accidental, since at time t = t0 = 5, all the cells are ready
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Fig. 44. Simulation results for the state transition model described in Fig. 43, with the
parameters N = 400, T = 20, µ1 = 15, σ1 = 2, µ0 = 8, σ0 = 2, t0 = 5, c = 0.2.
(a) gene expression distributions at different times, color coded from red to
blue; (b), corresponding population shifts. Note that the number of shifted
cells is the highest right after the onset time, and decreases gradually with
time.
to be transformed, and on average, N × c = 400 × 0.2 = 80 cells will switch to the
low-expression state. In the next time point t = 6, only about 400 − 80 = 320 are
left and, as a result, at the same transition probability a smaller number of cells will
be actually transformed to the low-expression state. As the pool of cells in a high-
expression state goes down, the number of transformed cells will also decrease. Such
behavior is not consistent with what we have observed in real experiments, where the
number of transformed cells per unit time starts at a low number, goes up quickly,
and finally returns to a low number (see Figs. 39(c) and 40 (b) for an example). Such
mechanistic difference suggests that the proposed model in Fig. 44 is overly simplified
and some of its assumptions may not be appropriate for real experiments.
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3. Different Onset Times for Different Cells
As the discussion in the previous section suggests, the assumption about identical
onset times for each cell in the cell line is too restrictive. Even in a homogeneous cell
line, all cells will compete for resources, such as nutrients, oxygen, etc. Moreover, it
is possible that different cells will stay at different stages of their cell cycle. Hence,
the micro-environment will differ from cell to cell, resulting in different, readiness,
or onset times. To account for such discrepancies, we consider a family of logistic
growth curves that describe the onset times for individual cells. Consider the logistic
function,
m(t) =
K
1 + e−r(t−t1)
(4.3)
where t is time, m = m(t) is the number of cells that have their cytoplasmic drug
concentration above the threshold level (i.e., ready to be transformed cells), r and K
are positive numbers, and t1 is an arbitrary time. The logistic curve introduced in Eq.
(4.3) is often used to model population dynamics in a resource limiting environment
and has been applied in many fields including ecology, biology, etc. As we can see
in Eq. (4.3), limt→∞m(t) = K. Hence, K is also called the carrying capacity. t1 is
the inflection point of the logistic curve. It gives the time for m(t) to reach the half
height. The parameter r will affect the rate of increase.
There are several reasons to choose the logistic curve as a model for cell onset
times. First, the carrying capacity K reflects the overall efficacy of the drug at a
particular dosage. For example, for a population of 400 cells, a carrying capacity of
100 indicates that at maximum, a total of 100 cells will be eventually transformed.
Second, the combined effect of r and t1 will determine how soon the cells will be
ready to be transformed, which is another important aspect of the drug effect. At
higher dosage, we expect to the logistic curve to have a higher carrying capacity as
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Fig. 45. Dosage dependent logistic curves to model cells’ onset times. m(t) is the
number of cells that are ready to be transformed. Higher dosage should rise
up earlier and have a higher carrying capacity K.
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Fig. 46. Simulation results for cell population with different onset times, with
N = 400, T = 25, µ1 = 15, σ1 = 2, µ0 = 8, σ0 = 2, c = 0.5. (a), (b), (c)
corresponds to the logistic curves in Fig. 45 for the black, red and blue curves
respectively.
well as an earlier rising period. Three hypothetical dosage dependent logistic curves
are shown in Fig. 45, where the blue curve corresponds to the highest dosage level
among all three.
Fig. 46 shows the simulation results for the three different cases in Fig. 46, with
N = 400, T = 25, µ1 = 15, σ1 = 2, µ0 = 8, σ0 = 2, c = 0.5. The number of transformed
cells per unit time starts low, goes higher with time, and eventually returns to 0.
Such behavior is consistent with real experimental observations. Moreover, the final
number of transformed cells is determined by the carrying capacity of the respective
logistic curve.
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Fig. 47. Parameter estimation using EM algorithm for the expression distribu-
tion in Fig. 46(c). As we can see, except from the earlier time
points, the estimated parameters agree very well with the true values
µ1 = 15, σ1 = 2, µ0 = 8, σ0 = 2.
C. Model Parameter Estimation
1. Estimating Model Parameters: µ1, σ1, µ0, σ0
One can estimate the means and variances in the proposed model directly from the
gene-expression distributions shown on Fig. 39(c). Given a mixture of Gaussian
distributions, it is standard practice in statistics to use Expectation-Maximization
(EM) algorithms to estimate the parameters of the individual components [75, 76].
Fig. 47 shows the EM algorithm estimation for the simulation results shown in Fig.
46(c), assuming equal variance of the individual components. Except for the earlier
time points, the EM estimation is very close to the true value. We also tested the
EM performance on real drug treatment experiment data (Fig. 48(a)). The results
are shown on Fig. 48(b). Interestingly, the estimated mean and variance are quite
flat, indicating that they might be time invariant.
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Fig. 48. Parameter estimation using EM algorithm for a real drug experiment (MKI67
responses to Lapatinib at dosage 2uM). The flatness of the estimated param-
eters indicates that they are time invariant, agreeing with our model assump-
tions.
2. Estimating Model Parameters: The Onset Time t0
Estimation of the onset time is crucial to characterizing different dosage effects. As
explained in Section B.3, the onset time for different cells is assumed to be governed
by some logistic function. Hence, it suffices to estimate the three parameters in the
logistic function.
For simplicity, let us assume that once a cell has reached its onset time t0, it will
immediately transform from the expression state 1 to the expression state 0. That
is, we assume the transition probability ai,110 = c in Fig. 43 (b) to be 1. In such a
situation, the population shift dynamics is completely governed by the logistic curve,
i.e., the number of actually transformed cells at time t is equal to the number, m(t),
of cells ready to be transformed. Hence, we want to find r and K and t1 in Eq. (4.3)
to minimize the square error [77]:
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e =
T∑
t=1
(m(t)− n(t))2 (4.4)
where m(t) is defined in Eq. (4.3) and n(t) is the observed number of transformed cells
at time t. To minimize the least square error in Eq. (4.4), we define m(t) = Kh(t),
where
h(t) =
1
1 + e(−r(t−t1)
Hence, we can rewrite the error e to be
e = ||KH −N ||2 = K2 <H ,H > −2K <H ,N > + <N ,N > (4.5)
whereH = (h(t = 1), h(t = 2), . . . , h(t = T )),N = (n(t = 1), n(t = 2), . . . , n(t = T )),
and <X,Y > denotes the inner product. To minimize e, we set its partial derivatives
with respective to K equal to 0, ∂e/∂K = 0. Solving yields
K =
<H ,N >
<H ,H >
(4.6)
Now, substitute this result into Eq. (4.5) to get
e =<N ,N > −<H ,N >
2
<H ,H >
(4.7)
Eq. (4.7) contains just two parameters, r and t1, the parameter K being eliminated.
One can use gradient descent method to find r and t1 to minimize the error. K can
be computed from Eq. (4.6). Fig. 49 shows the results for fitting logistic curves
on 4 different dose response population-shift data. The closeness of the fitted curve
and the real data indicates that the proposed model for onset times provides a good
approximation. Also notice that, at low dosage, doubling the concentration almost
doubles K; however, at high dosage, doubling the concentration does not increase K
significantly. This indicates that the drug has reached the saturating effect at around
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16 uM.
D. Conclusion and Future Study
In this chapter, we propose a model to describe cell population gene-expression dy-
namics after drug treatment. Moreover, we show that under some simplified con-
ditions, the model parameters can be inferred from data and the parameters bear
useful biological implications, e.g. the carrying capacity K. Such model facilitates
systematic understanding of drug response dynamics, and therefore is useful for drug
development in general.
Along the same line of research, there are several interesting biological questions
to be answered. First, what is the source of GFP intensity variation from cell to cell?
As explained in the introduction section, the variation could be attributed to two
reasons: either internally (transcription bursts) or externally (random GFP cassette
insertion site). If it is due to the second reason, isolating a single cell from the cell
population and repopulate a monoclonal cell line from the single cell should eliminate
cell-to-cell GFP intensity variations, since the GFP insertion sites will be exactly
the same for the derived monoclonal cell line. On the other hand, if the source of
variation is due to transcription bursts, even the monoclonal cell line will still exhibit
the same degree of variations. Second, what affects the carrying capacity or the final
responded number of cells to a particular drug? As we have shown in the paper, the
carrying capacity is dosage dependent, and there seems to be a dosage level above
which the carrying capacity is saturated. Going a step deeper, why is this so? Is it
because the cell line is heterogeneous and there is a subpopulation of cells that are
immune to the drug? Or, is it because the drug has degraded after 48 hours and has
lost its potency? If it is due to the second reason, we should get an increase of the
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Fig. 49. Fitting logistic curves for population shift at different dosage levels. Circled
line: observed number of transformed cell; solid line: fitted logistic curve. K
is the estimated carrying capacity of the respective dosage. At low dosage,
doubling the concentration almost doubles K, however, at high dosage, dou-
bling the concentration does not increase K significantly. This indicates that
the drug has reached the saturating effect at around 16 uM.
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carrying capacity by replacing the cell media and refresh the drug after 48 hours. In
the future study, we plan to carry out experiments to answer those questions.
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CHAPTER V
CONCLUSION
In this dissertation, we have focused on applying engineering and statistical ap-
proaches to specific fields of cancer research with implications for designing drug
intervention strategies. Here, we summarize the main contributions of this work.
• We have proposed a model based framework for the characterization and de-
tection of master genes and canalizing genes. The framework can readily incor-
porate prior pathway knowledge, which is a unique feature that distinguishes
us from the non-model based approaches proposed previously [10,11]. We have
also shown how the detectability of master genes or canalizing genes is affected
by the various network structures and the associated parameters. The model
based approach ultimately enables us to unify the two concepts: both master
genes and canalizing genes tend to be the “hub” genes of the network; how-
ever, there are still subtle differences between the two: master genes measure
the ability to control while canalizing genes measure the ability of taking over
control.
• We have developed a time series alignment algorithm that can robustly and
accurately identify mechanistic similarities in drug responses. The algorithm
can facilitate large scale cancer drug MOA comparisons, which is a slow and
labor consuming process in the existing approach [19].
• We have proposed a Markov model that describes the gene expression dynamics
for a population of cells after drug treatment. Unlike the traditional method
that treats gene expression as an averaged behavior of a large number of different
cells, our approach models gene expression on the single cell level and therefore
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can account for cell to cell variabilities. This finer level characterization has
led to a deeper understanding of cell line based drug intervention strategies.
Motivated by the proposed model, we have also proposed a real experiment
that can uncover the source of GFP intensity variations from cell to cell.
Along the same line of research, there are several aspects that can be further
developed. First, the tree structured Bayesian network employed in Chapter II can
be extended to incorporate more complicated network structures. To do so, one
needs to infer Bayesian networks that are consistent with a set of predefined biolog-
ical constraints, i.e., the prior pathway knowledge. To our knowledge, such problem
has not yet been investigated in the Bayesian network research community. Second,
for the drug MOA study, our current approach focuses on the similarities on the
individual GFP reporter level; however, it is desirable to obtain a higher level simi-
larity representation by aggregating results from individual GFP reporters according
to their functional groups. Moreover, it is interesting to see if combining two drugs
will produce synergistic effect based on their individual MOAs, i.e., combinatorial
drug therapies. More experiments are needed to answer questions like: Is there a
subpopulation of cancer cells that are resistant to the applied drug? What are the
growth rates for each subpopulation if the cell line is heterogeneous? What is the
optimal dosage and frequency to apply a cancer drug? What are the critical missing
pieces in the pathway wiring diagram that render the failure of the applied drug? We
believe that all the aforementioned questions can be answered in a model based and
hypotheses driven framework similar as the ones used throughout this dissertation. It
is our hope that this work will generate enough interests and enthusiasms for others
to tackle those problems.
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